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Abstract 
 
Cardiovascular diseases (CVD) comprise the most common chronic disease 
worldwide. High lipid levels are a strong risk factor, making lipid-lowering statin 
therapy an important preventive measure.  
Here we explore the effects of common variants at the KIF6 and HMGCR loci on a 
range of cardio-metabolic traits and on response to statin therapy. While HMGCR is a 
well-established lipid-related locus, the role of KIF6 in response to statin therapy is 
controversial, and its contribution to related phenotype variability has not been 
clarified. 
We genotyped a coding KIF6 variant (p.W719R, rs20455) and two intronic ones in 
high LD to the former (rs9462535,rs9471077), as well as two non-coding variants in 
HMGCR (rs3761740 and rs3846662). Effects on 14 quantitative and 5 categorical 
cardiometabolic phenotypes including lipid-lowering therapy response were tested in 
a sample of 1,645 individuals from the Genetics in Brisighella Health Study (GBHS) 
from Italy and replicated in 10,662 individuals from the Estonian Genome Center 
(EGCUT). 
In GBHS the established HMGCR variant rs3846662 affects LDL cholesterol levels 
(P=8.5x10
-4
) while the intronic KIF6 variant rs9471077 modifies APOB levels 
(P=8.2x10
-4
). The latter association was confirmed in EGCUT. No significant 
association between KIF6 variants and response to statin therapy was observed. 
In the first genetic study involving GBHS we confirm the HMGCR effect on LDL-
Cholesterol and demonstrate a novel KIF6 effect on APOB. The latter association 
needs to be evaluated for its predictive value for overall CVD risk and its potential 
contribution to stratified patient care. 
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1. Epidemiologic studies in Italy and throughout the world 
 
1.1 Epidemiological approaches to heart disease 
 
The use of the word "epidemiology" and the concept of what epidemiology as a 
discipline may encompass has varied widely since the days of Peter Panum and John 
Snow. There are today many differing definitions of the word, but nearly all workers 
in the field will agree on one element of the definition: The word " epidemiology " by 
etymology refers to the study of something " which is thrust upon the people." There 
are still some who insist that epidemiology deals only with epidemics of infectious 
diseases, but current usage suggests that most workers would now agree that 
epidemiology deals with "the fundamental questions as to where a given disease is 
found, when it thrives, where and when it is not found in other words it is the ecology 
of disease"
1
without regard to whether the disease is believed to be infectious. Frost 
gave an analytical definition when he wrote that epidemiology "includes the orderly 
arrangement of facts into chains of inference which extend more or less beyond the 
bounds of direct observation. His definition might be called the essence of the" 
epidemiological method" except for the fact that it has been used by the physician 
since the time of Hippocrates to arrive at his clinical diagnosis. Thus, today, the 
epidemiological approach is used to explore certain relationships in health and 
disease which, with present technological methods, cannot be observed directly. In 
the field of cardiovascular diseases, studies using the epidemiological method have 
led to findings of considerable practical importance for prevention and treatment. 
 
1.2 The Brisighella Heart Study 
 
The Brisighella Heart Study is a prospective, population-based longitudinal 
epidemiological cohort involving 2939 randomly selected subjects, aged 14 to 84 
years, free of cardiovascular disease at enrolment, resident in the Northern Italian 
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rural town of Brisighella. The study was promoted in 1972 by Professor G. 
Descovich
2
. Subjects were clinically evaluated at baseline and every 4 years 
following enrolment when extensive clinical and laboratory data were obtained in 
addition to the assessment of morbidity and mortality. In 1986, the study became part 
of the WHO European Risk Factors Coordinated Analysis, and in 1990, it became 
part of the Risk Factors and Life Expectancy Project
3
. Throughout the duration of the 
entire study, all-cause mortality and morbidity, as well as the incidence of the main 
cardiovascular risk factors, were recorded. Every three months, the study design 
included an update of the database with regard to fatal and nonfatal new events and 
every four years, a complete medical check-up comprised a nutritional habits record 
and fasting blood sample was performed. From 1986 to 1988, several programs 
started to check efficacy, cost, and reliability of primary and secondary 
cardiovascular prevention, including school children and general population 
nutritional education programs and general practitioner training concerning 
therapeutic guidelines. Physical activity and nutritional habits have been recorded 
throughout the study and encoded as previously reported. The study was carried out 
in agreement with the Declaration of Helsinki. It was approved by the Ethical 
Committee, and all subjects gave their written consent to be involved in the study 
 
1.3 Framingham Heart Study 
 
Cardiovascular disease (CVD) is the leading cause of death and serious illness in the 
United States. In 1948, the Framingham Heart Study - under the direction of the 
National Heart Institute (now known as the National Heart, Lung, and Blood Institute 
or NHLBI) - embarked on an ambitious project in health research. At the time, little 
was known about the general causes of heart disease and stroke, but the death rates 
for CVD had been increasing steadily since the beginning of the century and had 
become an American epidemic. The Framingham Heart Study became a joint project 
of the National Heart, Lung and Blood Institute and Boston University. The objective 
9 
 
of the Framingham Heart Study was to identify the common factors or characteristics 
that contribute to CVD by following its development over a long period of time in a 
large group of participants who had not yet developed overt symptoms of CVD or 
suffered a heart attack or stroke. The researchers recruited 5,209 men and women 
between the ages of 30 and 62 from the town of Framingham, Massachusetts, and 
began the first round of extensive physical examinations and lifestyle interviews that 
they would later analyze for common patterns related to CVD development. Since 
1948, the subjects have continued to return to the study every two years for a detailed 
medical history, physical examination, and laboratory tests, and in 1971, the Study 
enrolled a second generation - 5,124 of the original participants' adult children and 
their spouses - to participate in similar examinations. 
In 1994, the need to establish a new study reflecting a more diverse community of 
Framingham was recognized, and the first Omni cohort of the Framingham Heart 
Study was enrolled. 
In April 2002 the Study entered a new phase, the enrollment of a third generation of 
participants, the grandchildren of the Original Cohort. In 2003, a second group of 
Omni participants was enrolled. Over the years, careful monitoring of the 
Framingham Study population has led to the identification of the major CVD risk 
factors - high blood pressure, high blood cholesterol, smoking, obesity, diabetes, and 
physical inactivity - as well as a great deal of valuable information on the effects of 
related factors such as blood triglyceride and HDL cholesterol levels, age, gender, 
and psychosocial issues. Although the Framingham cohort is primarily Caucasian, the 
importance of the major CVD risk factors identified in this group have been shown in 
other studies to apply almost universally among racial and ethnic groups, even though 
the patterns of distribution may vary from group to group. In the past half century, the 
Study has produced approximately 1,200 articles in leading medical journals. The 
concept of CVD risk factors has become an integral part of the modern medical 
curriculum and has led to the development of effective treatment and preventive 
strategies in clinical practice. 
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The Framingham Heart Study continues to make important scientific contributions by 
enhancing its research capabilities and capitalizing on its inherent resources. New 
diagnostic technologies, such as echocardiography (an ultrasound examination of the 
heart), carotid artery ultrasound, magnetic resonance imaging of the heart and brain, 
CT scans of the heart and its vessels and bone densitometry (for monitoring 
osteoporosis), have been integrated into past and ongoing protocols. 
While pursuing the Study's established research goals, the NHLBI and the 
Framingham investigators are expanding their research into other areas such as the 
role of genetic factors in CVD. One project under way will utilize genetic material 
from immortalized cell lines of all of our cohorts. Framingham investigators also 
collaborate with leading researchers from around the country and throughout the 
world on projects in stroke and dementia, osteoporosis and arthritis, nutrition, 
diabetes, eye diseases, hearing disorders, lung diseases, and genetic patterns of 
common diseases. The unflagging commitment of the research participants in the 
NHLBI Framingham Heart Study has made more than a half century of research 
success possible. We continue with an ambitious research agenda and look forward to 
new discoveries in the decades to come.
4
 
 
1.4 KORA Study 
 
Referent subjects were drawn from the KORA S4 study, with ages ranging from 
25-74 years. The KORA S4 study is a population-based epidemiological survey of 
persons living in or near the city of Augsburg, Southern Germany conducted between 
1999 and 2001. The survey population consisted of German nationality residents born 
between July 1, 1925 and June 30, 1975 identified through the registration office. A 
sample of 6640 participants was drawn with ten strata of equal size according to sex 
and age, and 4261 individuals (66.8%) agreed to participate. 
KORA - The Kooperative Gesundheitsforschung in der Region Augsburg Study 
(KORA) is a series of population-based epidemiological surveys of persons between 
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25 and 75 years old at the time of enrollment living in or near the city of Augsburg, 
Southern Germany. KORA F3 was conducted between 2004 and 2005, and KORA 
S4 was conducted between 1999 and 2001. In 1644 randomly selected individuals 
from F3 and 1027 from S4, genome-wide genotyping was performed. In KORA F3 
and S4, 12-lead resting ECGs were recorded with digital recording systems (F3: 
Mortara Portrait, Mortara Inc., Milwaukee, USA, S4: Hörmann Bioset 9000, 
Hörmann Medizinelektronik, Germany). PR interval was measured automatically. In 
addition all ECGs were visually inspected for technical errors and inadequate quality. 
The Mortara portrait determines PR intervals by a proprietary algorithm, PR intervals 
from Hörmann Bioset were determined using the Hannover ECG analysis software 
(HES-Version 3.22-12) by computerized analysis of an averaged cycle computed 
from all cycles of the 10 second recording after exclusion of ectopic beats. PR 
intervals determined by this algorithm represents the earliest begin of atrial 
depolarization until the earliest deflection of ventricular depolarization between any 
two leads. In an international validation study the HES-software was among the best 
performing digital ECG systems. Reproducibility of HES measurements over short 
and long term time intervals has been investigated and KORA data have been used in 
several genome-wide association studies of quantitative EKG traits.
5
 
 
1.5 Chris Study 
 
Background: The meaning of CHRIS (Cooperative Health Research In South 
Tyrol) captures the essence and purpose of the project itself: it is a prospective 
epidemiological research study centered around the health of people living in South 
Tyrol. It represents a true partnership between the people participating, the staff 
working in the health care system and the research personnel of the Centre for 
Biomedicine at EURAC. 
The prevalence of chronic diseases is slowly but constantly increasing, due both to 
the aging of the population and to better diagnostic procedures. At the same time, 
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diagnosis is often made after the illness is established, when preventative medicine 
has less chance of success. In many cases no effective preventative measures are 
known. Common diseases such as cardiac or respiratory disorders, diabetes or 
neurological conditions have many unanswered questions: What causes such 
diseases? What role does lifestyle, genes or a person's environment play in the onset 
and progression? Are there interactions between any of the influential factors for 
positive or negative outcomes? 
Prospective cohorts are perfect models for epidemiological studies: they are large 
groups of people that are followed over time (every 4/5 years) and from whom 
clinical parameters, medical history, and life-style information, such as diet, physical 
activity, and exposure to environmental factors (e.g. coffee drinking and smoking 
habits), are progressively collected. With such information we can begin to assess the 
extent to which some of these factors, alone or together with genetic susceptibility, 
can explain some of these common diseases, their severity or lack thereof. 
The CHRIS Study is an ambitious project that raises from the collaboration between 
the Local Health System and EURAC, and that aims to involve individuals aged 18 
or older by taking part of an interview, enrolling in a quick free clinical assessment, 
and by providing a small sample of blood. 
Participation in the CHRIS Study is completely voluntary. Individuals participating 
will get a feedback on some of the health parameters being measured, taking the first 
step towards proactive prevention and improved personal health. Equally important, 
their participation will provide the local health system with insights for the creation 
of preventive medicine plans, laying the foundation for improved health care for all 
of the people of South Tyrol. Finally, participants will aid in the creation of what we 
hope will be one of the most important research centers in the medical field focusing 
on neurological and cardiovascular diseases. Epidemiological studies need several 
hundreds or thousands of people to confirm the goodness of their results. 
For this reason the CHRIS Study will also bring its contribute to a much larger 
epidemiological study that will be ongoing in Germany (German National Cohort), 
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which aims to answer the same questions by collecting information from 
approximately 200,000 individuals. The CHRIS Study started in August 2011.
6
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2. Biobanks of epidemiological studies 
 
2.1 The Biobanks 
 
Over the past two decades, the explosion in biomedical research since the 1950s, 
together with important technical advances in high-throughput analysis, has resulted 
in the creation of an increasing number of facilities for the long-term storage of 
human cell and tissue samples for research. Despite significant differences in 
approach, purpose, scale, and scope, these facilities are now collectively known as 
“biomolecular resource collections” or simply “biobanks”. 
When “biobanks” were first reported in the European science press almost 15 years 
ago, they were greeted with a healthy dose of scepticism and, on occasion, with 
outright fear. At least to some, the proposal by the Icelandic biotechnology firm 
deCODE to build an exhaustive database of genetic linkages between all Icelanders 
raised fears of a new kind of “big brother”, with access to our family history and 
genetic makeup and funded by US American venture capitalists. 
Since then, much has changed. For example, large biobank projects throughout the 
world are now aiming at sequencing the entire genome of tens of thousands of 
individuals. At about the time deCODE started its endeavour, the private company 
Celera Genomics raised around US$300 million to assemble the first full sequence of 
a single human genome, while a parallel public sector project spent probably billions 
of US$ on the same task. Over the past years, the cost of genome sequencing has 
dropped considerably and, if we are to believe the announcements from a number of 
companies developing new sequencing equipment, in only a few years the cost of 
sequencing the entire genome of a person will cost less then a few hundred US$. 
But, while inexpensive genome sequencing may well be a necessary prerequisite for a 
new area of genome-informed, personalized medical care, cheap sequencing alone is 
far from sufficient when it comes to extracting real medical benefits from genome 
research. Thus, apart from a few singular cases, for many years to come the main 
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beneficiaries of inexpensive genome sequencing will not be patients but, rather, 
biomedical scientists. 
In this new world of clinical genomics, where the entire genomes of tens of thousands 
of individuals will be readily available, the role and importance of biobanks which 
link physiological samples to medical and biomedical information, such as whole 
genome sequence data will become ever more important. But, future biobanks are no 
longer simply organizations that collect, and store, peripheral blood samples, and 
then make them available to scientists and, in this fashion, limit the potential risks 
ranging from a breach of confidentiality to the violation of a informed consent 
agreement that an investigator faces when dealing with human-derived materials or 
genetic information. Rather, we believe biobanks will increasingly turn into strong 
and trusted partners of both medical scientists and the public and, especially, the 
invisible community of biobank “donors” or “participants”. * In this report we 
advocate a novel approach toward biobank governance; an approach where biobanks 
are no more simply service institutions for the scientific community, but active, and 
reliable partners of both the scientific community and the public in the pursuit of 
genomic medicine. As we have seen, biobanks have a long history, starting with the 
pathology collections of the late 18th and early 19th century. Further, with the rise of 
biomedical research during the second half of the 20th century, first in the United 
States and more recently in Europe, numerous collections of human materials for 
specific research purposes were created. 
There exist several hundred human materials collections in Europe today, and these 
number does not include smaller collections that individual scientists have gathered 
during the course of their research. The vast majority of these collections is linked to 
a single research laboratory, or department, and has been built over time, often as part 
of a long-term research objective. The users of these collections are typically limited 
to a small number of scientists, and rarely extend beyond the immediate collaboration 
network of those collecting the resources. Most of these small tissue banks were 
started by scientists in areas such as cancer research, where human tissues are used 
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extensively. Many of these collections remain limited in size, and investment, and are 
typically known only to insiders, or the agencies or institutions that fund them. And, 
until very recently, few would actually label themselves as “biobanks”.7 
 
2.2 BBMRI-ERIC 
 
Essential for the understanding of the diversity of human disease, biological 
samples and corresponding data are required for the development of any new drug or 
diagnostic assay and are therefore critical for the advancement in health research, 
ultimately leading to personalized medicine. Biobanks also will provide key 
information on the influence of environment and lifestyle on health constituting a 
basis for disease prevention programmes and the improvement of public health. 
Hence a close collaboration between researchers, biobankers, patient advocacy 
groups, and biotech and pharma industry is essential in addressing both common and 
rare disease. Keeping in mind the need for better prevention, diagnostics, and therapy 
for all we are aware that every single sample impacts our ability to comprehend 
disease and, thus, achieve our goal for healthier life. Sixteen Member States and one 
International Organisation have thus joined forces in establishing BBMRI-ERIC, 
which is one of the largest health Research Infrastructure in Europe today and has 
recently been joined by the United Kingdom. BBMRI-ERIC primarily aims at 
establishing, operating, and developing a pan-European distributed research 
infrastructure of biobanks and biomolecular resources. This will facilitate the access 
to biological resources as well as biomedical facilities and support high-quality 
biomolecular and medical research. 
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The mission 
 
BBMRI-ERIC will increase efficacy and excellence of European bio-medical 
research by facilitating access to quality-defined human health/disease-relevant 
biological resourced through. 
- the inclusion of associated data in a efficient and ethically and legally 
compliant manner 
- by reducing the fragmentation of the bio-medical research landscape through 
harmonisation of procedures, implementation of common standards and 
fostering high-level collaboration 
- by capacity- building in countries with less developed biobanking communities 
thereby contributing to Europe’s cohesion policy and strengthening the ERA. 
 
The History 
 
The ESFRI Roadmap: 2006 
 
The European strategy Forum on Research Infrastructures developed and published 
the European Roadmap on Research Infrastructure to propose research facilities of 
pan-European interest, among them BBMRI. 
 
The Preparatory Phase: 2008-2011 
 
In 2008, BBMRI was one of the first projects entering the Preparatory Phase (PP)of 
the ESFRI Roadmap for Research Infrastructures. Funded by the European 
Commission’s Framework Programme 7, BBMRI-PP was granted 5M Euro to 
conceptualise and secure funding for the construction of BBMRI. Within three years, 
BBMRI-PP grew into a 54 member consortium with more than 225 associated 
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organisations from over countries, making it one of the largest research infrastructure 
projects in Europe. 
The project content and action plan of BBMRI-PP were defined in the Grant 
Agreement with the European Commision. The seven Work Packages of BBMRI-PP 
were responsible for the specific deliverables, with the goal of integrating the existing 
quality-controlled biobanks, biomolecular resources and enabling technologies into a 
novel pan-European biomedical research infrastructure. The major achievements of 
BBMRI-PP are summarised in the Final Report to the European Commision, 
including its operational concept as outlined in the Business Plan. 
 
The interim Phase: 2011-2013 
 
After three years, the BBMRI-PP project came to its end 31 January 2011, including 
the Governance and Management Structures, which were based on the Grant 
Agreement. In its final teleconference on 25 January 2011, the BBMRI-PP. Steering 
Committee agreed that the Coordinator, the Executive Manager as well as the 
steering Committee of Preparatory Phase should continue to function as interim 
bodies of BBMRI until the preparatory governance body was established.  
Building on achievements of BBMRI-PP, the FP7-project BBMRI_LPC aims at 
helping scientist to access large prospective study sets with the vision that many parts 
will eventually integrate in BBMRI-ERIC. 
 
Awarded EU Legal Status: 3 December 2013 
 
After finalising the negotiations among interested member states and the ERIC 
application process, BBMRI-ERIC was founded with the publication the BBMRI-
ERIC statutes in the Official Journal of the European Union and entered into force 
three days after publication on 3 December 2013(Figure 1) 
Therewith BBMRI was officially awarded the community legal framework for a 
European research infrastructure consortium (ERIC). This specific legal form is 
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designed to facilitate the joint establishment and operation of research infrastructures 
of European interest. The Eric status allows pulling together biobanks and 
biomolecular resources into a pan-European facility and providing access to 
collections of partner biobanks and biomolecular resources, their expertise and 
services on a non-economic basis. On 21 January 2014, on the occasion of the 
European conference dedicated to the launch of Horizon 2020 in Vienna. 
 
Figure 1.The governance structure of bbmri-eric 
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3. Genetic polimorphisms modifying susceptibility to metabolic diseases and 
pharmacological therapy response 
 
3.1 Lipids and lipid metabolism 
The liver plays a key role in lipid metabolism. Depending on species it is, more or 
less, the hub of fatty acid synthesis and lipid circulation through lipoprotein 
synthesis. Eventually the accumulation of lipid droplets into the hepatocytes results in 
hepatic steatosis, which may develop as a consequence of multiple dysfunctions such 
as alterations in b-oxidation, very low density lipoprotein secretion, and pathways 
involved in the synthesis of fatty acids. In addition an increased circulating pool of 
non-esterified fatty acid may also to be a major determinant in the pathogenesis fatty 
liver disease.  
Lipid metabolism involves several pathways that are at least in part, inter-dependent 
and ‘cross-regulated’. The focus of the present discussion will be fatty acids and 
triacylglycerols. Fatty acids are the most commonly stored and circulating forms of 
energy, and triacylglycerols are the most common non-toxic form of fatty acids. Fatty 
acids/triacylglycerols may originate from four sources (pool input): De novo lipogen- 
esis, cytoplasmic triacylglycerol stores, fatty acids derived from triacylglycerols of 
lipoprotein remnants directly taken up by the liver, and plasma non-esterified fatty 
acids (NEFA) released by adipose tissue. The relative importance of these sources 
depends on species differences (e.g. in ruminants, only modest amounts of hepatic De 
novo lipogenesis occurs com- pared with adipose tissue; the inverse is true in birds, 
with liver being the main site of De novo lipogenesis), and on short- and long-term 
nutritional status and energy balance. Fatty acids and triacylglycerols may also be 
used in different ways (pool out- put). Triacylglycerols may accumulate in 
hepatocytes (while NEFA or activated forms of NEFA may not) unless NEFA are 
oxidized (more or less completely) or triacylglycerols are exported as constituents of 
very low density lipoproteins (VLDL). Two examples of inter-connection may be 
cited: (i) a low rate of esterification when the oxidation rate is high in response to 
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energy demand, (ii) a strong relationship between VLDL secretion and fatty 
acid/triacylglycerol availability; this is especially the case in species where De novo 
lipogenesis is very active, but not in those species where high triacylglycerol 
concentration may be present and where the liver is not the ‘usual’ site of De novo 
lipogenesis. The triacylglycerol content of hepatocytes is regulated by the activity of 
cellular molecules that facilitates hepatic fatty acid uptake, fatty acid synthesis, and 
esterification (‘input’) and hepatic fatty acid oxidation and triacylglycerol export 
(‘output’). Moreover, and interestingly, fatty acids regulate overall lipid metabolism 
by binding nuclear receptors that modulate gene transcription. 
Lipids are a group of natural molecules that include fats, waxes, sterols, of which the 
most important is cholesterol, soluble vitamins (such as A, D, E and K), 
monoglycerides, diglycerides, triglycerides, phospholipids. Dietary lipids of 
physiological and especially pathological importance include triglycerides, which 
account for 90% of dietary lipid, cholesterol esters, phospholipids and the fat soluble 
vitamins. Lipids represent the most concentrated source of calories in the diet. 
The human diets contain variable amount of triglyceride and cholesterol provided by 
diet. Typical Western diets provide as much as 40% of the total calories in the form 
of triglyceride, but, on a worldwide scale, this type of diet is geographically and 
historically unusual. Most dietary triglyceride is absorbed in the duodenum and 
proximal jejunum after undergoing partial hydrolysis in the gut lumen. Triglycerides 
are mechanically mixed with the aqueous secretions of gastrointestinal tract to form 
large fat droplets. Then a smaller emulsion of smaller fat droplets is formed as bile 
acids, and phospholipids from the diet and bile become associated with the droplet 
surface. These substances are amphophilic, i.e., partly hydrophilic and partly 
hydrophobic, and thus promote the formation of a stable oil
8
water interface. These fat 
droplets are continuously exposed to the enzymatic activity of lipases. This 
enzymatic activity releases monoglycerides and free fatty acid (FFAs). At the same 
time, action of a pancreatic phospholipase on the phospholipid associated with the 
droplet surface leads to the formation of lysophospholipids and FFAs. The FFAs and 
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monoglycerides that are converted back to triglycerides are those that have chains at 
least 14 carbon atoms long. Shorter chain fatty acid largely pass through the epithelial 
cells and are transported via the portal vein to the liver
9
,
10
. Once reached the 
bloodstream, chylomicrons are hydrolysed by lipoprotein lipase (LPL) releasing 
triglycerides, which in turn will be absorbed to the luminal surface of capillaries. 
Most of FFAs released in this way are taken up by adipose cells, and stored as 
adipose tissue triglyceride. Over the passages chylomicrons change in composition; 
they lose phospholipid and apo-lipoproteins AI, AII and AIV and take up cholesterol 
and apo-lipoproteins CI, CII, CIII and apo E. Apo CII it is known to be particularly 
important because it affects the clearance of chylomicron triglyceride from the 
plasma, by activating LPL. Thus, patients with a familial apo CII deficiency develop 
hypertriglyceridemia and hyperlipidaemia when they ingest fat because chylomicrons 
accumulate in the plasma
11
,
12
. The other lipid particularly important is a key 
component of cell membrane. 
Its role in the membrane composition seems to be due apparently to its amphophilic 
character and its unique, rigid structure, that allows it to intercalate between 
membrane phospholipids. This intercalation markedly decreases the permeability of 
membranes to water-soluble molecules and also decreases membrane fluidity
13
. 
Although a dietary requirement for cholesterol doesn’t exist, cholesterol introduced 
with diet significantly participates to a pool of cholesterol and its bile acid products 
that circulate several times each day between the intestine and the liver. Cholesterol 
introduced daily by diet can range up to 0.5/1.0 g/day and most part of this 
cholesterol is in the form of cholesteryl ester and probably is not directly absorbed. 
Cholesterol absorption is incomplete and only 30-60% seems to enter body pools
14
.It 
seems to be likely that cholesterol absorption is realized by soluble, lipid-carrier 
protein that bring it from the microvillus membrane to the intracellular site of 
lipoprotein synthesis. The cholesterol absorbed, once within the epithelial cells, 
mixes with the intracellular pool of cholesterol, is esterified again with fatty acid and 
enters the chylomicrons, which also contain small amount of free cholesterol. After 
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the chylomicrons enter the plasma and are attacked by LPL, much of this cholesterol, 
particularly the cholesterol ester, becomes associated with chylomicron remnants. 
The remainder of the cholesterol and also the remaining phospholipid apparently 
become associated with high density lipoprotein (HDL). Chylomicron remnants 
contain apo- E, which interacts with its receptors localized on the surface of 
hepatocytes, and thanks to this interaction chylomicrons are rapidly removed from 
plasma into hepatocytes
15
.The ingested particles are hydrolysed within secondary 
lysosomes to yield amino acids, FFAs, and unesterified cholesterol. One effect of the 
influx of chylomicron remnant cholesterol into the liver is the decreased synthesis of 
endogenous cholesterol because of reduced hydroxyl- methylglutaryl-CoA reductase 
(HMGCoAreductase) activity. This is the rate-limiting enzyme of cholesterol 
biosynthesis and catalyses the conversion of HMG CoA to mevalonic acid, the first 
committed metabolite in the biosynthesis of cholesterol. It is subject to multivalent 
feedback suppression by sterols and by non-sterol products of mevalonic acid
16
,as 
well as to phosphorylation and dephosphorylation
17
.Down regulation and inactivation 
of HMG-CoA reductase by these mechanisms leads to diminished formation of 
hepatic cholesterol, which limits the tendency of dietary cholesterol to increase 
hepatic cholesterol levels. The most part of cholesterol synthesised ex novo by the 
liver or introduced with the diet is either converted into bile acids or secreted directly 
into bile
18
. One type of lipoprotein secreted is very low density lipoprotein (VLDL), 
also involved in the triglyceride transport; indeed, VLDL of hepatic origin consists of 
a core of triglyceride stabilized by a thin film of phospholipid, unesterified 
cholesterol, apo- lipoproteins B100, C, and E. Into the peripheral tissue VLDLs are 
metabolized by LPL, that catalyses the partial hydrolysis of the triglyceride, 
producing remnant lipoproteins. These cholesterol-rich remnants may be taken up 
directly by the liver or may continue to circulate in the plasma and be gradually 
converted into small lipoproteins known as low-density lipoproteins (LDLs) that 
delivery cholesterol to peripheral cells. LDL show a diameter that is one fourth to one 
third of the diameter of the parent VLDL, and show a core that is made chiefly by 
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cholesteryl ester surrounded by phospholipid, unesterified cholesterol, and apo-B. 
The net effect is the formation of a cholesterol-rich lipoprotein that is small enough to 
be transported across the endothelial cells of peripheral capillaries. The conversion of 
VLDL to LDL usually requires about 12 h, after which LDLs are gradually cleared 
from the bloodstream, principally by two mechanisms, one receptor-dependent, and 
another nonspecific mechanism such as pinocytosis. The best understood mechanism 
is that mediated by LDL receptor, which bind lipoproteins that contain apo-B and/or 
apo-E with a high affinity. Once interaction between receptor and lipoprotein is 
realized, complex is internalized by adsorptive endocytosis. Vesicles formed by this 
process subsequently fuse with lysosomes, whereupon the lipoproteins are degraded 
by lysosomal hydrolases and unesterified cholesterol is released into the cytosol. As 
cytosolic cholesterol accumulates, it is esterified by an intracellular acyl CoA-
cholesterol acyltransferase (ACAT) or used to form membranes. At the same time, 
increased cytoplasmatic cholesterol levels, activates feedback mechanisms that 
reduce intracellular HMG-CoA reductase activity and down-regulate the LDL 
receptor. These feedback mechanisms clearly limit both the intracellular synthesis of 
cholesterol from acetyl CoA and the uptake of excessive amounts of LDL cholesterol. 
In the LDL clearance process an important role is played by LDL-receptor and apo-B 
and E, whose importance is emphasized by the strikingly high concentrations of LDL 
that are typically found in the plasma of patients affected by familial 
hypercholesterolemia
19
.  
Familial hypercholesterolemia may be caused by incapacity of our body to form 
functional apo-B and E receptors and/or inability to internalize lipoproteins. Cells 
that normally show LDL receptors include fibroblast, smooth muscle cells, 
adrenocortical cells, luteal cells from the ovary. Thus, these receptors are widely 
distributed over tissues and organs, accounting for about two thirds of the removal of 
LDL particles from plasma
19
. The LDL receptors are usually localized into 
cytoplasmatic vesicles and are subject to a recycling process, according to the 
intracellular requirements for cholesterol. For example, since LDL it has been seen to 
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play a key role in delivering cholesterol to endocrine cells that synthesise steroid 
hormones, under corticotropin stimulation the LDL receptor number increases 
highly
20
. 
In addition to secreting VLDL, the liver secretes lipoproteins referred to as nascent 
high density lipoprotein (HDL), a heterogeneous class of lipoproteins, which have in 
common a high density (>1.063 g/mL) and a small size. These lipoproteins contain 
phosphatidilcoline, unesterified cholesterol, and apo-AI or E. Mature HDL3 and 
HDL2 are synthesised from lipid-free apo-AI or lipid-poor pre-β1-HDL as the 
precursor. These precursors are released from lipolysed VLDL and chylomicrons or 
are produced as a nascent HDL by the liver orintestine. After being secreted into 
plasma, nascent HDLs interact with a plasma enzyme that also is synthesised and 
secreted by the liver. This enzyme, lecithin-cholesterol acyltransferase (LCAT), 
forms cholesteryl esters in plasma by transferring fatty acids from HDL 
phosphatidilcoline to HDL unesterified cholesterol. The LCAT enzyme is activated 
by apolipoproteins, in particular by apo-AI, that is the principal apo-lipoprotein 
component of mature, circulating HDL. Differences in the quantitative and 
qualitative content of lipids, apolipoproteins, enzymes, and lipid transfer proteins 
result in the presence of various HDL subclasses, which are characterized by 
differences in shape, density, size, charge, and antigenicity
21
.Lipoproteins not only 
deliver cholesterol to cells but apparently also contribute to reverse cholesterol 
transport (RCT). Cholesterol in peripheral cells in the form of cholesteryl ester is 
hydrolysed by an intracellular cholesteryl ester hydrolase
22
. Then, on interaction of 
cells with HDL that is transiently bound to HDL receptors on the cell surface
23
, the 
liberated unesterified cholesterol transfers to the plasma membrane and becomes 
associated with the HDL. RCT describes the metabolism and an important anti-
atherogenic activity of HDL, namely, the HDL-mediated efflux of free cholesterol 
from non-hepatic cells and its subsequent delivery to the liver and steroidogenic 
organs, in which cholesterol is used as a precursor for the synthesis of lipoproteins, 
bile acids, vitamin D, and steroid hormones
24
,
25
. 
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Approximately 9 mg cholesterol per kg body weight is synthesized by peripheral 
tissues every day and must be moved to liver for effective catabolism
26
. Alteration of 
RCT can lead to a deposition of free cholesterol (FC) within the arterial wall and 
thereby contributes to the development of arteriosclerosis. Evidence that HDLs 
contribute importantly to reverse cholesterol transport is provided by the 
abnormalities that accompany Tangier disease. This inborn error of metabolism is 
characterized by abnormally low level of HDL in the plasma and by the presence of 
cholesteryl ester-rich foam cells (macrophages) in peripheral lymph nodes. Several 
lines of evidence suggest that cholesterol efflux may be realized by three different 
mechanisms: aqueous diffusion, SR-BI-mediated FC efflux, and ABCA1-mediated 
efflux. Cholesterol molecules are sufficiently water-soluble to transfer from cell 
membrane to an acceptor by the aqueous diffusion mechanism
27
. This process 
involves desorption of cholesterol molecules from the donor lipid-water interface and 
diffusion of these molecules. through the intervening aqueous phase until they collide 
with and are absorbed by an acceptor. The aqueous diffusion mechanism involves a 
simple diffusion process, and, as such, cholesterol transfer is passive and driven by 
the cholesterol concentration gradient. In this mechanism process, the unstirred water 
layer surrounding cells creates a significant diffusion barrier
28
. The other mechanism 
of cholesterol efflux is based on the interaction between acceptor and SR-BI 
receptors of donor. These receptors are members of the CD36 family of proteins and 
share about 30% sequence homology with the other members of this family
2930
. 
Besides stimulating the efflux of free cholesterol, expression of SR-BI also facilitates 
the influx of free cholesterol, thus, the movement of free cholesterol is bidirectional 
and the net movement depend on the cholesterol concentration gradient, like to the 
aqueous diffusion. Furthermore, besides mediating the bidirectional flux of free 
cholesterol, SR-BI is able to induce a selective uptake of other lipoprotein lipids, 
including cholesteryl ester, phospholipid, and triglyceride
31
.This movement is 
unidirectional, and by promoting the net flux of HDL cholesteryl ester and 
triglyceride, SR-BI induces depletion of HDL core lipids. SR-BI receptors interact 
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with a wide range of acceptors, including HDL, LDL, oxidized LDL, acetylated LDL, 
and small unilamellar vesicles
32
. 
The last mechanism of free cholesterol efflux is mediated by ABCA1. This receptor 
is a member of a large family of ATP-binding cassette transporters that have common 
structural motif and use ATP as an energy source to transport a variety of substrate, 
including ions, lipid, and cytotoxins. In contrast to SR-BI, the preferred cholesterol-
acceptors for ABCA1 is a lipid-poor apo-lipoproteins. All of exchangeable apo-
lipoproteins, such as apo AI, Apo AII, Apo AIV, Apo E, and Apo C can act as 
phospholipid and cholesterol acceptors for ABCA1
3334
. ABCA1 promotes the 
unidirectional efflux of cholesterol and phospholipids to lipid-free or lipid-poor apo-
lipoprotein, and is also involved in the lipidation of apo-lipoprotein AI in the 
formation of nascent HDL. It has been demonstrated by several studies that a direct 
interaction between cholesterol transporter and apo-lipoprotein play an important role 
in ABCA1-mediated efflux. ABCA1 has been seen to cross-link with the Apo-AI, 
indicating a very specific association between them. These results are confirmed by 
recent studies conducted by Fitzgerald et al., that show as four different mutant 
ABCA1 transporters with missense mutation exhibited little or no Apo-AI-induced 
efflux or cross-linking to Apo-AI. This result suggest that a direct interaction between 
Apo-AI and ABCA1 is necessary for efflux. Plasma lipoprotein can also be removed 
by less specific mechanisms. Macrophages and endothelial cells possess a scavenger 
receptor that recognizes modified LDL (i.e. oxidized LDL). The uptake of modified 
lipoproteins by this scavenger pathway has been hypothesized to contribute to the 
deposition of cholesterol in atherosclerotic plaques
35
. 
 
3.2 Dyslipidaemia: hypercholesterolemia and hypertriglyceridemia 
 
The term dyslipidaemia encompasses abnormalities of lipoprotein transport 
associated with a decrease of lipids in plasma, hypolipidaemia, as well as those 
causing an excess, hyperlipidaemia. The definition of dyslipidaemia has gradually 
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evolved as a result of advances in the understanding of the underlying mechanisms. 
Many monogenically-inherited disorders can now be defined in terms of the specific 
mutation(s) responsible for encoding the dysfunctional receptor, ligand or enzyme 
causing dyslipidaemia, whereas most polygenic and secondary forms of 
dyslipidaemia are still defined by arbitrary cut-offs such as the 5th and 95th 
percentile of the distribution of the lipid or lipoprotein variable in question. 
In a similar manner the classification of dyslipidaemia has evolved from the 
Fredrickson and World Health Organization classifications of lipoprotein phenotypes 
devised over 30 years ago to the simpler system now in use. This includes both 
hypolipidaemia and hyperlipidaemia and differentiates the latter into 
hypercholesterolaemia, hypertriglyceridaemia and mixed hyperlipidaemia. 
Speaking of hyperlipidaemia or dyslipidaemia, we are referring to 
hypercholesterolemia, hypertriglyceridemia or both. These hyperlipidaemias may be 
primary or secondary. Secondary hyperlipoproteinaemias are the complication of 
underlying, metabolic disturbances, drug-induced effects, or the result of dietary 
excesses. Otherwise, primary hyperlipoproteinaemias are genetically determined and 
may be classified by lipoprotein phenotype or genotype. The genetic classification 
may be subdivided into monogenic (caused by single-gene inheritance) and 
polygenic-multifactorial (caused by multiple subtle genetic factors that act together or 
in combination with environmental factors)
36
.Primary hyperlipidaemia has been 
classified into six types, based on the specific patterns of the various lipoproteins in 
plasma. (Table 2) 
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Table 2.Primary Hyperlipidaemia classification based on lipoprotein phenotype 
 
However, these types of pattern are not specific, and the plasma lipoprotein pattern 
may change with the time in any individual. Abundant evidence supports the 
importance of abnormal lipoprotein metabolism in atherosclerotic disease and more 
in general in cardiovascular disease. Several epidemiological studies have 
documented that diets reach of saturated fats and cholesterol accelerate atherogenesis. 
The prominent alterations that are consistently related to atherogenesis include 
hypercholesterolemia (reflecting increased concentration of LDL), 
hypertriglyceridemia (reflecting increased concentration of VLDL and/or remnants 
and triglyceride enrichment of LDL and HDL), increased apo-B levels, and reduced 
levels of HDL and its apo-AI
37
. Since different animals are able to form lesion of 
atherosclerosis similar to human when they develop hypercholesterolemia, it has been 
possible to understand the cellular changes that come into play in the atherosclerotic 
plaque formation. Faggiotto et al. focused on this particular issue adding new 
important informations
38
. These data show that the first and most striking event 
occurs after 7 to 14 days of diet-induced hypercholesterolemia. The Lipid Research 
Clinical Trials results it seems quite clear as lowering of plasma LDL levels would be 
extremely beneficial. Furthermore, it has been seen either in animal models either in 
human patients aggressively treated with lipid-lowering regimens a regression of 
atherosclerotic plaque, fatty streaks, significant reduction in the size of the smooth 
30 
 
muscle proliferative lesions, with a consequent benefits in atherosclerosis, myocardial 
infarction, and coronary artery disease. Brown and colleagues have demonstrated a 
statistically significant regression of semiocclusive lesions of human coronary 
atherosclerosis in association with decreases in plasma cholesterol and LDL 
levels
39
.These results provide clear evidence of pathological role of cholesterol and 
more in general of lipids. 
 
3.3 Lipid pathway: role of HMGCR and  KIF6 
 
HMGCR (3-Hydroxy-3-Methylglutaryl-CoA Reductase) is a Protein Coding gene. 
Diseases associated with HMGCR include Alzheimer disease 
17 and mevalonicaciduria. Among its related pathways are regulation of cholesterol 
biosynthesis and metabolism.  HMG-CoA reductase is the rate-limiting enzyme for 
cholesterol synthesis and is regulated via a negative feedback mechanism mediated 
by sterols and non-sterol metabolites derived from mevalonate, the product of the 
reaction catalyzed by reductase. Normally in mammalian cells this enzyme is 
suppressed by cholesterol derived from the internalization and degradation of low 
density lipoprotein (LDL) via the LDL receptor. Competitive inhibitors of the 
reductase induce the expression of LDL receptors in the liver, which in turn increases 
the catabolism of plasma LDL and lowers the plasma concentration of cholesterol, an 
important determinant of atherosclerosis. Alternatively spliced transcript variants 
encoding different isoforms have been found for this gene.  
Three major superfamilies’ of microtubule motor proteins have been identified, 
kinesin, myosin, and dynein. Kinesin is a wide superfamily constituted by 45 
members expressed in mammalian cells, which share analogies in the motor domain 
but differ considerably in their cargo-binding tail domain
40
. Although KIFs are 
conserved between species, many different types exist within a single organism, 
suggesting that KIFs might have diverged through molecular evolution to mediate 
different cellular functions. Conventional kinesin, also known kinesin-1, and most of 
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the other vesicles motors in the kinesin superfamily move unidirectionally toward the 
plus end of the microtubule
41
. Thus, kinesins are likely to be involved in the in 
trafficking events directed toward the cell periphery, such as motility from the Golgi 
to the plasma membrane. However, other minus end-directed kinesins also contribute 
to intracellular trafficking events, such as the minus end-directed transport of early 
endosomes
42
. The intracellular transport is essential for appropriate cellular 
morphology and function. Kinesin proteins have been seen to transport organelles, 
protein complexes, and mRNA to specific site along the microtubule while 
hydrolysing ATP for energy. Kif6 is a member of the kinesin 9 family but the precise 
molecular function of kif6 is still not known, and in particular its association with the 
circulating cholesterol level is not understood. It is likely to play a role in the cellular 
transport of proteins along microtubules and could be involved in cellular transport in 
the cardiovascular system. To date, all studies have focused on investigating 
polymorphism in the KIF6 gene within the context of coronary artery disease even if 
its molecular pathway needs to be clarified. Indeed, there has been considerable 
debate regarding the role of KIF6 in coronary artery disease. Several lines of 
evidence that used a candidate gene based approach in several atherosclerosis 
population cohorts have observed an increased risk of adverse coronary events in 
carriers of the rs20455 C variant in the KIF6 gene which lead to a Trp719Arg 
substitution in the Kif6 protein. 129,130 However, these results were refuted by a 
large part of Genome-Wide-Association-studies metanalysis using 19 case control 
studies where cases were defined either by a history of prior myocardial infarction 
and/or the presence of coronary artery disease at angiography. Furthermore, no 
association between the KIF6 variant and this pathological condition has been found 
in the most recent large meta-analysis. Nevertheless, evidence from international 
randomized controlled trials with statins associated carriage of Tpr719Arg genotype 
with a greater clinical response to statin therapy. Another study, JUPITER trial, has 
been realized on a wide population of patients, men and women, without prior 
cardiovascular disease or diabetes, were randomly allocated to rosuvastatin 20 
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mg/day or to placebo and followed for first major vascular events and for all causes 
of mortality. The effects of Tpr719Arg polymorphism have been evaluated. 
Outcomes obtained from this study didn’t show any correlation between genotype 
and major cardiovascular risk factors, as well as no clinically meaningful differences 
in pharmacological response have been seen between carriers and non-carriers. 
 
3.4 Pharmacology of lipid metabolism 
 
Lipid regulating drug therapy is indicated in patients with coronary heart disease 
(CHD) and high-risk individuals in whom dietary and lifestyle measures have failed 
to control dyslipidaemia. Because this is usually a life-long commitment, the use of 
these drugs should be the exception rather than the rule in asymptomatic patients, 
being restricted to those with severe hyperlipidaemia of genetic origin, such as 
familial hypercholesterolaemia (FH), or in whom the presence of other risk factors 
results in an unacceptably high risk. The opposite applies, however, to patients with 
clinically manifest CHD, in whom even mild dyslipidaemia requires vigorous drug 
therapy aimed at achieving target levels stipulated in guidelines. 
The rationale for the use of lipid regulating drugs is based on the large body of 
evidence from epidemiological and clinicpathological studies that points to the 
central role of cholesterol in atherosclerosis. Confirmation that the association is 
causal comes from numerous angiographic and clinical end- point studies showing 
that lipid-lowering therapy slows the rate of progression of atherosclerotic lesions in 
coronary, carotid and femoral arteries, and reduces the frequency of associated 
cardiovascular events. The best proof of causality derives from the atherogenicity of 
low density lipoprotein (LDL) and the evidence that lowering LDL cholesterol arrests 
or reverses the process. Loss of the protective effect of high density lipoprotein 
(HDL), resulting from a decrease in plasma levels, also has strong epidemiological 
support, but the evidence that raising HDL cholesterol is beneficial is less 
compelling. Likewise, although increasing epidemiological and angiographic 
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evidence suggests that triglyceride-rich remnant particles play a role in promoting the 
progression of mild-to-moderate lesions in coronary arteries, more data are needed on 
whether lowering triglyceride prevents CHD events. Hence, it is not surprising that 
the current therapeutic emphasis is on lowering LDL cholesterol. That said, there is 
increasing interest in developing compounds that raise HDL cholesterol and could be 
used as an adjunct to LDL-lowering drugs. 
As it has been mentioned above, several lines of evidence from epidemiological and 
biochemical studies have demonstrated the importance of reducing to physiological 
level lipids concentration and in particular total cholesterol and LDL concentration. 
Indeed, it has been well demonstrated over the years that a linear relationship 
between LDL-C levels and relative risk for CHD exists, as showed in  
Figure 2 below: 
 
 
 
Figure 2 .Linear correlation existing between LDL-C and Relative Risk for CHD 
demonstrates the high importance to keep total cholesterol level and LDL within a 
physiological range suggested from the international guidelines for cholesterol level 
(Grundy et al. Circulation2004; 110(2):227-239). 
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According to the World Health Organization (WHO), LDL cholesterol level ranging 
from 100-130 is considered optimal, >160 high, >190 very high; Total Cholesterol is 
considered desired < 200, borderline between 200-239, and high ≥240; HDL 
cholesterol <40 is believed low, ≥60 high (Table 3). 
 
 
Table 3.Classification of lipids level in the blood and acceptance risk according to 
the international guidelines. 
 
Risk factors such as diet, smoking, physical inactivity, obesity, high blood pressure, 
lipids (high LDL and low HDL cholesterol and raised triglycerides), diabetes, family 
history of coronary heart disease are responsible of a huge number of cases of 
coronary heart disease. The World Health Organization (WHO) believes that 60% of 
coronary heart disease and 40% of strokes are due to elevated LDL cholesterol levels. 
Reducing LDL-C has long been the primary target of cholesterol policy and this 
remains the case today. The two major approaches of LDL-lowering therapy are 
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therapeutic lifestyle changes (TLC) and drug therapy. Dietary therapy should be the 
first approach in all form of lipid disorders. Although there is a great variation in 
individual response to a low-fat, low-cholesterol diet, changes of alimentary habits 
can be expected to play a significant role in improving most lipid profile. The 
minimal goals of dietary therapy should be to reduce LDL cholesterol to under 160 
mg/dl and lower the total cholesterol to under 240 mg/dl in patients without CAD or 
two additional risk factors and to less than 130 mg/dl if any of these conditions apply. 
Drug treatment of lipid disorders should not be used until a precise diagnosis. Before 
to start the drug lipid-lowering therapy, maximum dietary effort should be done. To 
date, there are several classes of lipid-lowering drugs which act at a different levels of 
cholesterol biosynthesis, such as bile acid sequestrants (Cholestyramine, Cholestipol), 
Nicotinic acid, Fibric acid derivatives (Gemfibrozil, Clofibrate), HMGCoA-reductase 
inhibitors (Statins).(Table 3) Cholestyramine and Cholestipol are quaternary 
ammonium salts that act as anion-exchange resins, binding bile salts in the intestine 
tract. This sequestration leads to a reduction of reabsorption of bile salts and 
consequently to a decrease of their enterohepatic recycling; in the same time there is 
an increase of bile salts excretion in the stool. The positive effects on lipid-lowering 
of this class of drugs is represented by the fact that cholesterol will be used for an ex-
novo synthesis of bile salts rather than be used for LDL or VLDL synthesis. 
Cholestyramine and Cholestipol are considered first line agents and are highly 
effective in decreasing LDL cholesterol
43
. The niacin is able to reduce the LDL levels 
by about 25% and VLDL levels by about 75%.Furthermore, this drug is able to 
increase the HDL levels by 20 to 40%. Similarly to bile acid resins, nicotinic acid’s 
activity, is accompanied by frequent side effects, that include cutaneous flushing and 
gastrointestinal (GI) symptoms. Gemfibrozil and clofibrate are the fibric-acid 
derivatives widely used in USA; in Europe, fenofibrate, benzafibrate, and ciprofibrate 
are also used. The fibric-acid derivatives are used in VLDL and triglycerides 
lowering. Their mechanism of action is not completely clarified, even if they seem to 
act by increasing lipoprotein lipase activity via peroxisome proliferator activated 
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receptors-α; this action leads to an increase of VLDL clearance44.The last class, not 
for importance, of lipid-lowering drug is represented by 3-hydroxyl-3- methyl-
glutaryl-CoA-reductase inhibitors, the so-called statins: atorvastatin, pravastatin, 
lovastatin, rosuvastatin, and simvastatin. This class of drugs is the most extensively 
used in the treatment of hypercholesterolemia. The efficacy, safety, and benefits of 
statins make them the drugs of choice. Statin are able to lower the serum low-density 
lipoprotein and triglycerides levels, and in the same time they increase the HDL 
levels. Furthermore, it has been seen that statins offer an important contribution to the 
reduction of the risk for the major cardiovascular events, such as MI and death for 
CVD in selected population. Side effect of statins are principally muscle-related 
(such as muscle weakness) and in general mild in nature. More serious side effects, 
such as myopathy and fatal rhabdomyolysis are rare and often can be seen when 
statins are used in combination with other medicines that affect statin 
pharmacokinetics
45
. Usually statins are used singularly, even if there are several cases 
in which statins are used in combination with other lipid-lowering drugs. However, 
doubts about the benefits of statins, alone or in combination with other lipid-lowering 
drugs, remain. In patients with a very high LDL levels or mixed dyslipidaemia that 
fail to reach the desired lipids levels on statin monotherapy, other classes of drugs are 
often added in order to improve clinical outcomes. Besides the co-administration, 
another aspect of statin therapy that remains difficult for prescribers is the ability to 
predict individual patient’s response to therapy, in terms of efficacy and genetic 
predisposition to possible adverse effects
46
. Plasma concentration of statins as well as 
the pharmacological efficacy can vary widely amongst patients that receive the same 
dose of the same statin. Recent results obtained from pharmacogenomics and 
pharmacogenetics studies have demonstrated a wide number of candidate genes (40 
gene) that are involved in the modulation of statin pharmacokinetics and 
pharmacodynamics. Doubtless, the most important is the gene expressing for the 
HMGCoA-reductase enzyme. Statins act binding to the catalytic domain of 
HMGCoA-reductase enzyme that, as above said, catalyses the rate-limiting step of 
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cholesterol biosynthesis. All statins share rigid, hydrophobic groups that are 
covalently linked to the HMG-like moiety. All statins are competitive inhibitor of the 
natural substrate HMGR, and it has been seen that they act occupying the HMG-
binding pocket and part of the binding surface for CoA, thus sterically preventing 
substrate from binding. Comparing the complex obtained between the natural 
substrate and the enzyme or between a statin and the enzyme, a clear rearrangement 
of the substrate-binding pocket has been seen after the statin interaction. The strong 
efficacy of statin’s interaction with the catalytic site of HMGCoA-reductase is 
probably due to the large number of van der Waals interaction, which in turn reflects 
the importance of each amino acid that takes part in the catalytic site's constitution. 
Several studies have shown as structural changes of catalytic site of HMGCoA-
reductase, principally caused by genetic alteration, lead to a loss of statin treatment 
efficacy. (Table 3) 
 
Daily dose Mean change (%) 
 LDL-C HDL-C TG 
Atorvastatin 40 mg 
Nicotinic acid 4 g 
Gemfibrozil 1.2 g  
Ezetimibe 10 mg  
Colestyramine 24 g 
-51 
-9 
-18 
-18.5 
-23 
+5 
+43 
+12 
+3.5 
+8 
-32 
-34 
-40 
-4.9 
+11 
TC, total cholesterol; LDL-C, low density lipoprotein cholesterol; HDL-C, high 
densitylipoprotein cholesterol; TG, triglyceride. 
Table 4. Comparative effects of lipid regulating drugs 
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3.5 Modulation of statin pharmacokinetics and pharmacodynamics and  
individualized therapy 
 
Individual variability in drug efficacy and drug safety is one of the most important 
challenge in current clinical practice of this century and the personalized therapy 
seems not to be a dream anymore. In a large patient population, a medication that is 
demonstrated efficacious and safe in many patients, it is proven to be inefficacious 
and sometimes lethal in some other peoples. Although large individual variability in 
drug efficacy and safety has been well documented amongst peoples since the 
beginning of the medicine, its understanding still represents an unmet need. The 
demonstration of individual variation in drug response has proven difficult, even if 
the demand to overcome such variation has received more attention and become the 
goal of modern medicine. It is well known that large variability of drug efficacy and 
adverse drug responses in patients is a major determinant of the clinical use, 
regulation, and withdrawal from the market of clinical drugs. Drug response is 
influenced by several factors, some of which involve important aspects that are 
intrinsic to the biology itself. Genetic variation in humans was recognized as the most 
important determinant of individual variability of drug response from clinical 
observations in late 1950s
47
,
48
. From these studies it has been observed amongst a 
certain population differences in plasma concentration of specific drugs and in the 
similar way also differences of metabolites concentration in urine, demonstrating that 
variances in pharmacodynamics and pharmacokinetics are present and exert a very 
important role. It has been seen that in some patients a very low or a very high 
concentration could be present and the biochemical traits leading to the variation of 
drug concentration were found inherited. These clinical findings fostered the 
formation of pharmacogenetics. Differences of drug response and behaviour reflect 
sequence variations of specific genes coding for drug targets, such as proteins, drug 
metabolizing enzymes, receptors, drug-transporters
49
,
50
. Starting from these 
outcomes, the availability of the complete human genome sequence has made it 
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possible to analyse the impact of variations of human genome sequence on the 
pathogenesis of important diseases and the response to drug therapy. The amount of 
knowledges and informations acquired over the years on genome-disease and 
genome-drug interaction has brought to a new area so-called pharmacogenomics 
starting from the previous pharmacogenetics. This goal provided a rationale for the 
hope that the personalized medicine can be achieved in the near future. Both 
pharmacogenomics and individualized drug therapy are increasingly influencing 
medicine, biomedical research, in many areas, including clinical medicine, drug 
development, drug regulation, pharmacology, toxicology. As already said drug 
efficacy and adverse drug reactions dose-dependently determine the clinical outcome 
of clinical therapy. To date, it is well known as these parameters change widely over 
the cohort and the personalized therapy, based firstly on a genetic screening and then 
on using of the right drug and concentration, may represent the only possible way to 
avoid to use an inefficacious drug and increase adverse drug reactions. We know that 
a higher dose boosts drug therapeutic effect but in the same time it increases the 
possibility to have undesirable side effects. The difference between the drug 
therapeutic effect and its side effects defines the so-called therapeutic window 
(Figure 3) 
 
Figure 3.Representation of dose-response curve. Panel A shows the therapeutic 
window, that is the difference between the efficacy and the toxicity. This window may 
vary from patient to patient, B and C, requiring dose-adjustment (Qiang Ma and 
Anthony Y. H. Lu, Pharmacogenetics, Pharmacogenomics, and Individualized 
Medicine, Pharmacol Rev 63:437–459, 2011). 
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For many drugs, the optimum dose required for effective and safe therapy varies 
significantly from patient to patient, because the minimum therapeutic dose can be 
too low or too high. Such a situation can be characterized by an atypical therapeutic 
window, dose response curve, and toxicity resulting in unexpected and undesirable 
outcomes. Genetic and non genetic factors affect individual variability of a drug 
response by modulating the dose response curves of drug efficacy and drug toxicity 
of patients. Clinical outcome is altered if drug dose is not adjusted accordingly. 
 
3.6 Genetic variation: SNPs 
 
Inherited differences in DNA sequence contribute to phenotypic variation, 
influencing an individual’s anthropometric characteristics, risk of disease, and 
response to the environment. A central goal of genetics is to localize the DNA 
variants that contribute most significantly to population variation in each trait
51
. The 
idea that genes control some drug responses was suggested for the first time in the 
1950 thanks to a correlation between inheritance or ethnicity and aberrant drug 
responses. This idea was strengthened by family and twin studies in 1960s 1970s, 
extended by biochemical studies in 1980s, and solidified by molecular genetics in the 
1990s
52,53,54
. Cloning and characterization of the first human gene containing DNA 
sequence variations, singular nucleotide polymorphisms, that influence drug 
pharmacodynamics and pharmacokinetics did not take place until the end of 
1980s
55
.Although there are a number of different types of polymorphic markers, most 
attention recently has focused on single nucleotide polymorphism (SNPs) and the 
potential for using these to determine the individual drug response profile. 
Polymorphisms are genetic variations of human genome that occur at a frequency of 
1% or greater in the population. These variations can appear as insertion or deletion 
of short fragments of nucleotide, even if the most common variations are SNPs. A 
SNP is a DNA sequence variation characterized by a singular nucleotide substitution 
among members of the same species or between chromosomes in an individual. SNPs 
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are the most abundant genetic variants in mammalian genomes and specifically in the 
human genome they account for 3.2 million and are responsible for the 90% of 
genetic human differences
56
. SNPs are classified in three different groups depending 
on where they are located in the genome: 1. c-SNPs, variations located in coding 
region, exons, whose presence could modify or not the amino acid sequence in the 
protein structure, defined as synonymous and non synonymous respectively 2. p-
SNPs are located in perigenic region, i.e., in regulatory regions such as promoter, 
enhancer, etc… Such polymorphism can modulate both the expression level and the 
stability of the protein, by influencing the mRNA stability. 3. r-SNPs, random SNPs 
that are located in the intergenic region, i.e., in those regions that do not show genes 
but that constitute the 98% of our genome. These variations are not able to influence 
the genetic expression. However they may alter the DNA structure by influencing the 
tertiary structure of DNA, and its capacity of interaction with chromatin or with 
enzymes such as topoisomerase. For these reasons, to date, we cannot exclude their 
implication in the pharmacogenetics. Currently there is a growing list of 
polymorphisms found in genes encoding of drug transporters and targets, drug-
metabolizing enzymes, as well as disease-modifying genes, that have been linked to 
drug effects in humans. Pharmacogenetics has indeed proven to be a potential source 
of biomarkers able to predict drug response and adverse drug reaction. For this 
reason, during the last decade a rapid development of techniques in the area of 
genome analysis has been seen and recognized as needful for the identification of 
new pharmacogenomics biomarkers. Such biomarkers mainly originate from genes 
encoding drug metabolizing enzymes, drug transporters, and drug targets. Some of 
these are now integrated by the USA Food and Drug Administration (FDA) and the 
European Medicines Agency (EMA) into drug label inserts
57
.Although the numerous 
potential benefits of pharmagenomics and pharmacogenetics have been announced 
and sometimes also demonstrated, to date, this innovative area of research is so rarely 
used in clinical practice. This seems to be a particularly relevant question that in the 
next year needs to be answered. It seems that the failure to use of this type of 
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approach in the clinical practice is related not only to scientific issues but also to 
cultural limits. For example, individualizing dosages, even based on easily assessed 
patients characteristics, such as sex, age, renal functionality, has not embraced by 
medical or pharmaceutical communities. Furthermore, there is a strong resistance to 
relying on tests for every medical decision. Not only does pharmacogenomics require 
a laboratory test, it also requires an interpretation of genotypes, which will probably 
require clinicians to receive further training in molecular biology or genetics. Lastly, 
it also difficult to demonstrate that individualization of drug therapy on the basis of 
genetics improves clinical outcomes, given the multigenic nature of most drug 
effects. These represent just some of limits that can hinder the clinical use of this 
discipline. 
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4 Role of KIF6 and HMGCR polymorphisms in variability of 
cardiometabolic phenotypes and response to statin therapy in the Brisighella 
cohort 
 
4.1 Introduction 
 
 Cardiovascular diseases (CVD) encompass a wide range of pathological 
conditions, including raised blood pressure, hypertension, ischaemic and coronary 
heart disease, cerebrovascular disease, heart failure
58
. To date, CVDs represent the 
number one leading cause of mortality and morbidity with an estimated number of 17 
million of deaths/year in the world, projected to reach 23.3 million by 2030
59,60
. 
Several lines of evidence from epidemiological and biochemical studies have widely 
established that high level of low-density lipoprotein cholesterol (LDL-C), low 
concentration of high-density lipoprotein cholesterol (HDL-C), and high level of total 
cholesterol (TC) play a pivotal role for the development of CVD, and moreover can 
be considered as important factors in the neurodegenerative pathology. In particular, 
high LDL-C is causally associated with coronary artery disease (CAD).Triglyceride 
levels have been associated with coronary artery disease (CAD)
61
. The diagnostic and 
predictive value of LDL-fractions as apolipoprotein B (APOB) has so far only been 
investigated in smaller studies.  
To date, amongst the great body of lipid-lowering drugs, statins are the most used 
worldwide and represent the cornerstone of lipid lowering strategy. However, 
reduction of statins prices, related to wide availability of generic drugs, further adds 
to an increase in their prescription specially in subjects at lower estimated CVD 
risk
62
. Despite large randomized controlled trials have well-documented the 
effectiveness of statins in reducing circulating LDL-C levels and CVD events, several 
issues have been noted in their use. In particular, response to the same dosage of 
similar types of statins varies among patients; in addition, to date, there are no 
established criteria to prevent their adverse effects, such as myalgia and 
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rhabdomyolysis. Genetic factors are thought to come into play in the inter-individual 
variations of response to statins
63,64
. Thus, elucidating genetic variation in patients 
undergoing statin therapy may enable tailored treatment, thereby optimizing efficacy 
as well as minimizing costs and adverse effects. Over the past decade, more than 40 
loci in human genome have been described with respect to the differential effect of 
statins on decreasing the risk of clinical endpoints including cardiovascular death and 
myocardial infarction (MI), and on modulating lipid levels
59,60,65,66
. 
Amongst these, common variants at Kinesin Like-Protein 6 (KIF6) gene have seen 
the most controversial observations. KIF6 is a homodimeric molecule belonging to 
the KIF9 family of kinesins, a big superfamily of motor proteins that are involved in 
variety of processes in the eukaryotic cells, such as cell division, cytoplasm 
organization and intracellular microtubule transportation of protein complexes, 
organelles and mRNA, KIF6 is a relatively recent candidate for CVD, initially 
suggested as contributing to cardiovascular risk within the European population
67
. 
Specifically, a common non synonymous SNP, rs20455 resulting in a missense 
Tryptophan to Arginine substitution at position 719 of the codified polypeptide chain 
(p.W719R, Trp719Arg) has been widely studied since 2007
68,69
. In a meta-analysis of 
seven prospective studies it has been demonstrated that heterozygous and 
homozygous carriers of the KIF6 719Arg variant were at an increased risk to develop 
CVD and received a significant benefit from the statin therapy compared to 719Trp 
homozygous wild type individuals
70
. However, contradictory results have been 
reported by subsequent studies for this variant role in statin therapy response
59,71,72,73
. 
Moreover, variants within KIF6 locus have never been reported in association with 
lipids levels in large genome-wide association studies (GWAS), therefore its role in 
regulating statin therapy response is not defined. 
An important and well established factor in statin-responsive lipid and lipoprotein 
concentrations is the 3-Hydroxy-3-Methylglutaryl-Coenzyme A reductase (HMG-
CoA reductase)
74
. KIF6 and HMGCR are potentially both involved in the pathway of 
lipid-lowering statin drugs. Genetic effects of HMG-CoA reductase (HMGCR) and 
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KIF6 genetic polymorphisms have been extensively studied individually, however no 
studies have investigated their combined effects on bloodstream lipid levels 
modulation.  
In this study, we aimed to investigate the role of KIF6 variants in the body 
metabolism through analysis of association with cardiometabolic phenotypes, 
including14 quantitative traits and 5 categorical disease outcomes, including 
categorical response to statin therapy, in the GBHS and EGCUT population-based 
samples of up to 12.307 individuals. We used established lipid locus HMGCR variant 
as proof-of-principle analysis for this first genetic study from GBHS. 
 
4.2 Materials and Methods 
 
4.2.1 Study populations 
 
The GBHS is a prospective, population-based longitudinal epidemiological 
investigation of genetic factors influencing a range of cardiometabolic phenotypes 
involving 2,939 randomly selected Caucasian subjects (1,491 men and 1,448 
women), aged 14 to 84 years, free of cardiovascular disease at enrolment, resident in 
the northern Italian rural town of Brisighella. The study started in 1972 and it is still 
ongoing. The town of Brisighella was originally selected as the site for the study, 
given a homogeneous life-style of its residents, with a very low rate of migration. 
Subjects were clinically evaluated at baseline and every four years thereafter by 
collecting an extensive amount of clinical and laboratory data. The GBHS protocol 
and its sub-studies, largely described elsewhere
75
,
76
have been approved by the Ethical 
Board of the University of Bologna and all volunteers involved gave their signed 
consent to participate in the study. 
For the purpose of this study, we randomly selected 1,645 subjects from the 
2008/2012 GBHS population survey, with available blood samples. 
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The Estonian Genome Center University of Tartu (EGCUT) is a prospective, 
volunteer-based sample of the Estonian resident adult population (aged ≥ 18 years). 
The current number of participants – close to 52,000 – represents a large proportion, 
5% of the Estonian adult population, making it ideally suited to population-based 
studies. General practitioners (GP) and medical personnel in the special recruitment 
offices have recruited participants throughout the country. At baseline, the GPs 
performed the standardized health examination of the participants, who also donated 
blood samples for DNA, white blood cells and plasma tests and filled out a 16 – 
module questionnaire on health-related topics such as lifestyle, diet and clinical 
diagnoses described in WHO ICD-10. Two independent samples of 2,589 and 8,073 
individuals from the EGCUT genotyped on Illumina370CNV and Illumina 
OmniExpress arrays, respectively and imputed to 2,5 Mio SNPs from HapMap were 
used for replication of results in follow-up. 
 
4.2.2 DNA extraction , Genetic analysis and quality control 
 
GeneCatcher™ gDNA Blood Kits (Invitrogen) The GeneCatcher™ Technology is a 
novel magnetic bead-based technology that is designed to work on a wide range of 
blood samples including archived or poorly stored blood samples to facilitate 
genomic DNA purification. 
The procedure is designed for isolating gDNA using theGeneCatcher™ Magnetic 
Beads procedure. (Figure 4) 
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Figure 4 .Procedure designed for isolating gDNA using theGeneCatcher™ Magnetic 
Beads procedure. 
 
The DNA quantification was done with the Quant-iT ™ dsDNA Broad-Range Assay 
Kit (Invitrogen) with a fluorescence microplate reader (Victor PerkinElmer) equipped 
with excitation and emission filters 510/527 nm appropriate for fluorescein. For 
genotypes analysis, we genotyped five selected SNPs: three in the KIF6 gene on 
chromosome 6, one non synonymous missense (rs20455) and two intronic 
(rs9462535, rs9471077, linkage disequilibrium from 1000 Genomes CEU database 
between the three SNPs 0.8<r
2
<1), and two in HMGR gene on chromosome 5, one 
upstream (rs3761740) and another intron 12(rs3846662, LD r
2
=0.215). 
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Genotyping was performed by real-time using the 5′-nuclease allelic discrimination 
assay (TaqMan®, Applied Biosystems, Foster City, CA), according to manufacturer 
instruction. Negative controls were included in each reaction as quality control. 
All five genotyped SNPs satisfied our quality control criteria with a call rate ≥95% 
and a Hardy-Weinberg equilibrium test p-value P>1x10
-4
. All minor allele 
frequencies (MAF) were >0.01(Table 6). We estimated linkage disequilibrium (LD) 
between genotyped SNPs (rs20455, rs9462535 and rs9471077 for KIF6, rs3761740 
and rs3846662 for HMGCR) in our sample using Haploview software and compared 
it to LD reported for 1000Genome CEU data . 
 
4.2.3 Phenotypes 
 
We analysed a total of 19 cardiometabolic phenotypes. Of these 14 were 
quantitative traits and 5 were binary outcomes including type 2 diabetes (T2D), 
coronary artery disease (CAD), hypertension (HTN), hypercholesterolemia (HTC) 
and categorical response to lipid-lowering therapy. Diseases were defined following 
the standard international guidelines
77,78,79
.Response to lipid-lowering therapy was 
defined only for patients that underwent lipid-lowering therapy, most of whom used 
statins at the time of sampling. These subjects were categorised as “responder” and 
“non-responder” to the therapy based on their value of for this study, we defined 
statin-resistant those subjects regularly taking a statin and who experienced an LDL-
C reduction of no more than 30% of the expected reducing efficacy of that drug at the 
given doses. 
Quantitative phenotypes included total cholesterol (TC), high-density lipoprotein 
cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides 
(TG), apoliprotein A1 (APOA1), apolipoprotein B (APOB), fasting glucose (FG), 
body mass index (BMI), waist circumference (WC), wrist circumference (WrC), 
height, systolic and diastolic blood pressure (SBP, DBP), heart rate (HR), serum uric 
acid (UR), creatinine (CREA).Following indication reported elsewhere
80,81,
 for lipids 
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we excluded individuals undergoing lowering-lipids therapy while for those 
individuals undergoing anti-hypertension therapy we added 15 mm Hg to SBP and 10 
mm Hg to DBP. 
To check the assumption of normally distributed quantitative traits, we performed a 
Shapiro-Wilk test on all such variables. Since normality test significantly deviated 
from normal distribution (p-value<0.05) for all phenotypes we applied an inverse 
normal transformation of residuals on all quantitative phenotypical variables. 
Residuals were calculated using linear regression analysis adjusted for specific 
covariates: all lipids and BMI were adjusted for sex, age and age
2
; FG, CREA, UR 
and height were adjusted for sex and age; anthropometric traits, DBP, SBP and HR 
were adjusted for sex, age, age
2
and BMI. Normality test and transformation of data 
were run using R software
82
. 
 
4.2.4 Association analysis 
 
For quantitative traits we assumed an additive genetic model of effects and 
applied a linear regression to transformed residuals after covariate adjustment. For 
categorical phenotypes we assumed log-additive genetic effects and implemented 
logistic regression. We adjusted the trait models for covariates as follows: T2D was 
adjusted for sex, age and BMI, CAD was adjusted for sex and age, HTC for sex, age 
and age
2
 and HTN for sex, age, age
2
 and BMI. 
All single variant association analyses were run using R and PLINK software in 
parallel
83,84
.Association analysis in two Estonian samples was run using SNPTEST 
software using maximum likelihood genotype estimates on imputed SNP array data
85
. 
Meta-analysis of results from three studies was performed using GWAMA 
software
86
.  
Association tests were Bonferroni corrected for multiple testing with 42 independent 
tests accounting for 14 non-highly correlated phenotypes (r<|0.5|, r
2
<0.25) and 3 
independent SNPs (as the three genotyped KIF6 variants are highly correlated 
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(0.8<r
2
<1) and were counted as one test) resulting in a study wide significance 
threshold of P<0,05/42 i.e. P<1,2x10
-3
. 
Gene-gene interaction between KIF6 and HMGCR loci variants in their effects on 
cardiometabolic phenotypes was tested using regression analysis with an interaction 
term to estimate effect between each pair of tested SNPs.  
Haplotype estimation was performed for KIF6 SNPs (0.8<r
2
<1) using PLINK 
software, followed by association analysis of haplotypes and diplotypes (i.e. 
haplotype genotypes) with cardiometabolic phenotypes. 
 
4.2.5 Phenotype correlation and multi-phenotype analysis 
 
We evaluated the correlation between analysed phenotype using the polycor 
package in R. hetcor function allow to perform a Pearson product-moment 
correlations test between quantitative variables, a polyserial correlation test between 
quantitative-discrete variables and a polychoric correlation test between discrete-
discrete variables. For those phenotypes that resulted highly correlated (|r|>0.5), we 
selected only the phenotype with less missing data to be included in the multi-
phenotype analyses. 
To check for pleiotropic effects of analysed variants on multiple cardio-metabolic 
phenotypes we run ordinal regression analysis using an implementation of the 
Multiphen algorithm
87
 in C++ code. In Multiphen the genotype of a marker is used as 
outcome variable, and the set of multiple phenotypes as predictors: for joint analysis 
of K phenotypes, we modelled the genotype, Gij, of the ith individual, at the jth 
variant, coded as 0, 1 or 2, according to the number of minor alleles it carries, as a 
linear function of phenotype values, yi, in a logistic regression framework. 
Specifically,  
, 
Where g
-1
 was the logit link function, αjwas the intercept, and βj was a vector of 
phenotype regression coefficients for the jth variant. Under this model, we obtained 
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maximum-likelihood estimates (and standard errors) of the phenotype regression 
coefficients and the corresponding deviance Dj defined as: 
 
with an approximate chi-squared distribution with n degrees of freedom, where lj is 
the log-likelihood of the jth logistic regression model and l0 is the log-likelihood for 
the null model. 
The Bayesian Information Criterion (BIC) score was selected as the optimal model fit 
statistic. BIC is defined as: 
 
Where lj is the log-likelihood of the jth logistic regression model, sj is the number of 
phenotypes in the model and n is the sample size (note that for a null model with 
intercept only, BIC0=-2l0 + log (n), where l0 is the log-likelihood for the null model).  
We run a logistic regression analysis to test for association with KIF6 
polymorphisms, correcting for age and BMI. As positive control, we tested also 
HMGCR polymorphisms. 
 
4.3 Results 
 
In the GBHS all the three variants in the KIF6 gene are in high LD (Figure 5). This is 
consistent with data reported for European samples from the 1000 Genome (1000G) 
data with r
2
rs20455-rs9462535= 0,86 (0.80 in 1000G), r
2
rs20455-rs9471077= 0,85 (0.80 in 1000G) 
and r
2
rs9471077-rs9462535=0,96 (1,00 in 1000G). The two variants in the HMGCR gene, 
instead, have a smaller correlation (LD) (Figure 6), lower than that reported in 
the1000 Genome data with r
2
rs3761740-rs3846662= 0,12 (0.22 in 1000G). 
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Figure 5.Locus view of the three investigated variants in the KIF6 gene. The view 
includes the gene structure of KIF6 and the linkage disequilibrium (r
2
) between the 
three SNPs 
 
 
 
 
 
We observed no association betweenKIF6 and HMGCR variants and response to  
Figure 6.  Locus view of the two investigated variants in the HMGCR gene. The view 
includes the gene structure of HMGCR and the linkage disequilibrium (r
2
) between the 
two SNPs 
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lipid-lowering therapy (i.e. the categorical phenotype “statin response” as defined in 
materials in methods) in 230 subjects from GBHS, including 134 responders and 94 
non-responders (Table 54). 
In the GBHS we replicated the association at HMGCR locus rs3846662 with LDL-C 
levels already reported in literature 
88
 (P=0.00085, and after Bonferroni correction for 
42 multiple tests (14 traits * 3 independent SNPs) Pcorrected=0.0357) (Table 5).  
Interestingly, HMGCR rs3761740 variant showed a significant association with SBP 
and DBP (p-valuec= 0.01285 and 0.0357, respectively) but the association was not 
significant after Bonferroni correction for 42 multiple tests. 
 
  KIF6 HMGCR 
 SNP rs20455 rs9462535 rs9471077 haplotype rs3761740 rs3846662 
 risk allele T C A ACT C G 
 other allele C A G GAT/GAC A A 
  risk allele 
freq. 
0.635 0.619 0.616 0.606 0.904 0.457 
TC beta 0.05365 0.06225 0.08123 0.0855 0.06065 0.1131 
 se 0.04018 0.04033 0.04022 - 0.06555 0.03735 
  pval 0.182 0.123 0.0436 0.0319 0.355 0.00251 
TG beta 0.09048 0.12101 0.11634 0.113 0.06269 -0.02634 
 se 0.04014 0.04024 0.04015 - 0.06555 0.03743 
  pval 0.0243 0.00268 0.00382 0.00459 0.339 0.482 
LDL-C beta 0.08837 0.08154 0.10358 0.106 0.035838 0.1254 
 se 0.04035 0.04053 0.04038 - 0.066263 0.0375 
  pval 0.0287 0.0444 0.0104 0.0079 0.589 0.00085 
HDL-C beta -0.12974 -0.10938 -0.1051 -0.101 -0.0051489 0.01972 
 se 0.04008 0.04028 0.0402 - 0.0655845 0.0375 
  pval 0.00124 0.0067 0.00903 0.011 0.937 0.599 
APOA1 beta -0.10598 -0.09433 -0.09094 -0.0863 0.037209 -0.007389 
 se 0.04123 0.04151 0.0414 - 0.066898 0.038384 
  pval 0.0103 0.0232 0.0282 0.0357 0.578 0.847 
APOB beta 0.1091 0.12246 0.13144 0.13 0.013194 0.06559 
 se 0.04085 0.04096 0.04079 - 0.066228 0.03797 
  pval 0.00766 0.00086 0.00082 0.00137 0.842 0.0843 
FG beta 0.02586 0.01042 0.01486 0.0391 -0.10199 -0.005246 
 se 0.03941 0.03944 0.03933 - 0.06283 0.036599 
  pval 0.512 0.792 0.706 0.316 0.105 0.886 
BMI beta 0.04548 0.03599 0.02809 0.00314 -0.0027122 -0.06371 
 se 0.03678 0.03674 0.03669 - 0.0603682 0.03462 
  pval 0.216 0.327 0.444 0.931 0.964 0.0659 
WC beta 0.011598 0.03176 0.03877 0.0369 -0.05687 -0.02493 
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 se 0.036959 0.03683 0.03677 - 0.06042 0.03476 
  pval 0.7537 0.3886 0.2918 0.313 0.3468 0.4734 
WirC beta -0.009856 0.0151 0.005258 0.00412 0.0007305 -0.005438 
 se 0.037937 0.03785 0.03777 - 0.0615324 0.03555 
  pval 0.795 0.6899 0.8893 0.912 0.9905 0.8784 
SBP beta 0.012364 0.02692 0.02037 0.0175 0.18191 -0.05053 
 se 0.036922 0.03682 0.03676 - 0.06025 0.03475 
  pval 0.738 0.465 0.58 0.632 0.01285 0.146 
DBP beta -0.004714 0.004176 -0.007108 -0.0144 0.1623 -0.03039 
 se 0.036968 0.036832 0.036788 - 0.06025 0.03479 
  pval 0.899 0.91 0.847 0.693 0.0357 0.383 
HR beta -0.01559 0.004266 0.01921 0.012 0.0877 0.06831 
 se 0.03796 0.037885 0.0378 - 0.06169 0.03567 
  pval 0.6813 0.9104 0.6114 0.75 0.1554 0.05571 
UR beta -0.03218 -0.03477 -0.02557 -0.0216 0.028311 -0.05321 
 se 0.03679 0.03672 0.03667 - 0.059787 0.03451 
  pval 0.382 0.3439 0.4857 0.552 0.6359 0.1233 
CREA beta -0.04357 -0.0558 -0.06174 -0.0637 0.0533 0.009019 
 se 0.03674 0.03664 0.03658 - 0.05967 0.034541 
  pval 0.2358 0.128 0.09164 0.0797 0.3719 0.794 
T2D beta -0.06142 -0.055759 -0.030537 0.0099503 0.162563 0.032447 
 se 0.15141 0.149095 0.148631 - 0.253219 0.146279 
  pval 0.8255 0.9523 0.8908 0.973 0.7104 0.9661 
HTN beta 0.021284 0.029566 -0.003233 0.0099503 0.402659 -0.1361429 
 se 0.088038 0.087797 0.087840   0.1436035 0.082461 
  pval 0.3255 0.4475 0.8477 0.878 0.05767 0.1891 
CAD beta -0.29514 -0.30918 -0.28848 -0.2484613 0.07424 0.02221 
 se 0.24145 0.23918 0.23962 - 0.41132 0.23632 
  pval 0.2972 0.2242 0.24 0.299 0.9151 0.7764 
HTC beta 0.138029 0.148877 0.173474 0.1906203 0.0097577 0.1433676 
 se 0.080282 0.080229 0.080170   0.1302524 0.0756111 
  pval 0.04539 0.058776 0.039708 0.0164 0.9891 0.02806 
Statin beta 0.004711 -0.105805 -0.106027 -0.1031407 -0.202124 0.2445135 
response se 0.32397 0.30384 0.30382 - 0.50637 0.33915 
  pval 0.3579 0.2649 0.2649 0.734 0.9569 0.3522 
 
Table 5: P-values reported in bold are significant before Bonferroni correction 
(P<0.05) while P-values reported in bold and italic are significant also after 
Bonferroni correction (42 independent tests, P<1.2x10
-3
) 
 
In the GBHS the KIF6 rs20455 (p.W719R) variant was associated with APOB levels 
(P=0.00766, Pcorrected=0.322) and HDL-C (P=0.00124, Pcorrected=0.0521) but both 
associations were no longer significant after Bonferroni correction for 42 tests.  
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The other two intronic and highly correlated KIF6 variants were both associated with 
APO-B levels, even significant after Bonferroni adjustment. (rs9471077-
G:P=0.00082, Pcorrected=0.0344 and rs9462535-A: P=0.00086, Pcorrected=0.0361). 
In GBHS both SNPs were also associated with higher levels of TG (p-
valuers9471077c=0.0191, p-valuers9462535c=0.0134), and lower HDL-C (p-
valuers9471077c=0.04515, p-valuers9462535c=0.0335) but not significant after multiple 
testing correction. 
Of these newly discovered associations, only the one between APOB levels and 
variants rs9471077 and rs9462535 was confirmed in replication analysis in two 
Estonian independent samples (Table 6). HMGCR association with blood pressure 
showed a similar trend towards association in replication cohorts. Results were 
significant when we applied a meta-analysis of GBHS results with results in the 
Estonian cohorts.  
Testing models that took into account also the interactions between KIF6 and 
HMGCR polymorphisms, we did not find any significant association with analysed 
cardiometabolic phenotypes. This indicates that there is no gene-gene interaction 
between KIF6 and HMGCR in our data. 
 
SNP Chromosome Position 
(hg19) 
Hardy-
Weinberg 
p-value 
Genotype 
call rate 
(%) 
MAF Alleles 
(Major/Minor) 
rs3761740 5 74632133 0,6962 99,9 0,096 C/A 
rs3846662 5 74651084 0,2 99,9 0,457 A/G 
rs9471077 6 39308742 0,1127 100 0,384 A/G 
rs9462535 6 39315792 0,1045 100 0,381 C/A 
rs20455 6 39325078 0,2982 99,9 0,365 T/C 
Table 6  Genotyping results: Statistics and quality control of the five SNPs 
investigated in this study 
 
We performed haplotype estimation at the KIF6 locus we observed three possible 
haplotypes comprising the three SNPs rs9471077-rs9462535-rs20455 : GAT 
(frequency=0.606), ACC (frequency=0.355) and ACT (frequency=0.023). 
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Interestingly, GAT haplotype was significantly associated with an increase of lipids 
values (0.001<P<0.03) confirmed also in the Estonian cohort only for APOB (Table 6). 
Significant association of ACT haplotype was also observed with risk of HTC (Table 
5). 
From the correlation analysis between considered phenotypes we identify three 
groups of highly correlated phenotypes (Figure 7): (1) SBP, DBP and HTN; (2) 
APOB, LDL and TC; (3) APOA1 and HDL. For each of these groups we retained 
only the phenotype with less missing data in our sample: SBP for the first group, 
LDL for the second one and HDL for the third one. 
 
Figure 7.Correlation analysis between considered phenotypes. Given are the values 
of the correlation coefficient r. Our analysis identified three groups of highly 
correlated phenotypes (r>|0.5|): (1) SBP, DBP and HTN; (2) APOB, LDL and TC; 
(3) APOA1 and HDL. For each of these groups we retained only the phenotype with 
less missing data in our sample: SBP for the first group, LDL f or the second one and 
HDL for the third one. 
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In multi-trait effect phenotype association analysis we tested the complete set of all 
14 quantitative and 5 discrete phenotypes included in our study. The multi-phenotype 
analysis showed the strongest association with individual phenotypes and did not 
identify any significant multi-trait effect for tested variants (Table 7): single 
phenotype models were most significant included HDL-C for rs20455, TG for 
rs9462535 and rs9471077, LDL-C for rs3846662 and SBP for rs3761740 with p-
values as low as P=0.00085.  
 
rs20455 
Phenotypes 
Set 
LogLikelihood nullLogLikelihood LikelihoodRatio P-value BIC BICnull Model 
set 1 -1647,2 -1651,39 8,37702 0,00379995 3308,68 3309,91 HDL-C 
set 2 -2152,88 -2155,64 5,50874 0,0189216 4320,57 4318,68 HTC 
set 3 -1647,2 -1651,39 8,37702 0,00379995 3308,68 3309,91 HDL-C 
rs9462535 
Phenotypes 
Set 
LogLikelihood nullLogLikelihood LikelihoodRatio P-value BIC BICnull Model 
set 1 -1669,49 -1674,07 9,14531 0,00249357 3353,27 3355,27 TG 
set 2 -2183,45 -2185,66 4,42991 0,0353145 4381,7 4378,73 HTC 
set 3 -1669,49 -1674,07 9,14531 0,00249357 3353,27 3355,27 TG 
rs9471077 
Phenotypes 
Set 
LogLikelihood nullLogLikelihood LikelihoodRatio P-value BIC BICnull Model 
set 1 -1671,37 -1676,04 9,33939 0,0022428 3357,02 3359,22 TG 
set 2 -2186,7 -2189,02 4,62811 0,0314522 4388,21 4385,44 HTC 
set 3 -1671,37 -1676,04 9,33939 0,0022428 3357,02 3359,22 TG 
rs3761740 
Phenotypes 
Set 
LogLikelihood nullLogLikelihood LikelihoodRatio P-value BIC BICnull Model 
set 1 -768,509 -772,454 7,8897 0,0049717 1551,3 1552,05 SBP 
set 2 -1034,87 -1035,78 1,82159 0,177124 2084,54 2078,96 HTC 
set 3 -768,509 -772,454 7,8897 0,0049717 1551,3 1552,05 SBP 
rs3846662 
Phenotypes 
Set 
LogLikelihood nullLogLikelihood LikelihoodRatio P-value BIC BICnull Model 
set 1 -1734,16 -1740,02 11,7256 0,000616467 3482,59 3487,18 LDL-C 
set 2 -2262,15 -2265,74 7,17982 0,00737281 4539,1 4538,88 HTC 
set 3 -1734,16 -1740,02 11,7256 0,000616467 3482,59 3487,18 LDL-C 
Table 7.P-values reported in bold are significant also after Bonferroni's corrections 
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4.4 Discussion 
 
In this genetic study in up to 12.307 individuals from GBHS and EGCUT 
studies we identified and validated a novel association of KIF6 variants with APOB 
levels, proved with several statistical approaches, including haplotype, single- and 
multi-phenotype analyses. This relationship is reported here for the first time and 
haven’t previously been explored either in lipid GWA studies, or in individual 
analyses. 
Apolipoprotein B is a carrier of lipids through the body to the tissues and is 
representative of the total number of atherogenic particles in the blood, since it binds, 
not only LDL-C, but also very low-density lipoprotein (VLDL) and intermediate-
density lipoprotein, large buoyant LDL-C, small dense LDL-C and lipoprotein(a)
90
. 
While APOB levels are rarely measured within large-scale studies, in contrast to 
other major lipid groups; many studies affirm that APOB level is a better measure 
than LDL and others to predict the risk of CVD and to evaluate the efficacy of statin 
treatment, than any other cholesterol index
91,92,93,94,95
. Based on these premises, the 
fact that KIF6 has never been associated with classic lipid (LDL-C, HDL-C, TG or 
TC), its debated effect on efficacy of statin therapy, and the significant association we 
found with APOB level may underlie the hypothesis under which genetic variants on 
KIF6 have an effect on susceptibility to statin treatment (in terms of risk of 
developing CVD) through an effect on APOB. This hypothesis, if confirmed by 
further studies, may help in setting up novel approaches of diagnosis and treatment 
for hyperlipidaemia and CVD. 
KIF6 has been reported as associated with differential benefit, in terms of CVD 
events, from lipid-lowering therapy with statins. In particular, the presence of 
rs20455-G variant had greater benefit
96,97
 suggested to act through an increased 
vulnerability to LDL cholesterol
98
. However, other studies have not confirmed such 
findings
99,100,101
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In our study, we did not find any significant association of KIF6 genotype at the three 
most studied polymorphisms with the response to lipid-lowering therapy, in terms of 
risk of fatal CVD outcomes in ten years. Additionally, we did not find any effect of 
interaction between the two studied genes, suggesting that KIF6 and HMGCR in our 
sample act on lipid levels through different pathways. 
We confirmed the association of HMGCR locus with lipids, already reported in large-
scale GWA meta-analyses
102,103
. Moreover, other unexpected associations were 
observed in GBHS, for example that of HMGCR with blood pressure. The replication 
of this association was obtained in a meta-analysis of our cohort with other two 
Estonian cohort, but was not significant in the two replication cohorts taken 
separately. These results may be because of more little effect of the gene on blood 
pressure in the Estonian cohort then in GBHS that might derive from exposition to 
particular influencing environmental factors in the Brisighella population, or from 
interaction with variants in other genes, which have bigger inter-population 
differences. 
The null findings from our study about role of KIF6 variants in statin therapy 
susceptibility may be due to a real lack of power, given the sample size. It can also be 
biased by the type of data used for the analyses. In fact, due to unavailability of 
longitudinal data, we used an estimation of the ten-year CVD risk instead of a real 
registration of CVD events. Moreover, most of the significant results reported in the 
literature are from studies of response to the therapy with an individual statin 
molecule
64,65,104
; in our data, instead, lipid-lowering therapy included a mix of several 
statin molecules (simvastatin, atorvastatin, rosuvastatin, fluvastatin) and that could 
have masked the effect on response to only one particular type of them. Additionally, 
other studies have suggested that KIF6 gene may reveal unexpected associations, 
when studied in single cohorts. Further studies, based meta-analysis of the literature 
and stratification for type of statin would be better suited to overcome these 
limitations. 
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Our study has some additional limitations. Firstly, the sample size of our discovery 
and replication sample is relatively small, further replication analyses in larger 
samples is required to confirm our novel findings. Moreover, the biological validity 
and clinical usefulness of the obtained results has to be verified using functional 
approaches, such as the one proposed by Shen and colleagues
105
. Finally, the set of 
cardiometabolic diseases used in our analysis has been chosen arbitrarily, even if the 
diagnostic cut-off applied are those suggested by the main specific international 
guidelines. 
Beyond that, the data are reliable and obtained from two European population-based 
studies, well-characterised and defined
106,107
. 
In conclusion, this study highlighted a novel effect of KIF6 variants on APOB levels, 
which might be predictive of CVD risk, but wasn’t sufficiently empowered to see the 
effect on statin therapy susceptibility. Further investigation of these findings would 
be important from additional studies. Additionally, evaluation of biological 
mechanisms underlying this mechanistic relationship will be better suited to uncover 
the biological relationship between the KIF6 gene and lipids metabolism, to advance 
our knowledge and possibly implement findings from this studies in more 
personalised approaches for CVD prevention and therapy. 
 
 
 
 
 
 
 
 
 
 
 
61 
 
5  Mendelian Randomization Analysis of associations between Serum Uric Acid 
and cardiovascular disease 
 
5.1 Serum Uric Acid 
 
In most mammals Serum Uric Acid (SUA), also known as Urate, is largely considered 
to be waste product of purine metabolism. In humans the kidneys excrete 70 percent 
of the metabolized SUA, yet circulating plasma SUA has also been shown to be 
associated with many physiological pathways in contrast to its waste product 
denomination
108
. Purine metabolism is an essential biological pathway that degrades 
excess purines such as Adeninemonophosphate (AMP), Adenosine, Guanine 
monophosphate (GMP), Guanosine, Inosine, and Hypoxanthine to SUA
109
 and is 
catalyzed by the enzyme Xanthine Oxidase (XO) (Figure 8). Most mammals further 
metabolize SUA to Allantoin, via the Uricase enzyme Urate Oxidase (UO) encoded 
by the Uoxgene. UO expression in man and higher primates has evolutionarily been 
suppressed by the inheritance and positive selection of several nonsense mutations 
that render the Uoxgene silenced
110
. Some evidence suggests that loss of UO 
expression may have imparted an evolutionarily advantage, and an interesting 
postulation by Orowan (1955), suggests a similar function of SUA to cerebral 
stimulants such as caffeine and theobromine in the rise of man. The Uox gene is 
considered to be truly ancient as it is observed and expressed in prokaryotes and 
eukaryotes
110
.Deregulation of SUA excretion and an inability to metabolize SUA, can 
lead to elevated levels of SUA (hyperuriceamia), which has been epidemiologically 
observed in many metabolic diseases such as Hypertension, Type 2 Diabetes (T2D), 
and Obesity, and elevated SUA is known to be the main cause of Gout
111
. Whether, 
SUA is a true risk factor, or just a compensatory response in these complex diseases 
still remain to be determined 
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Figure 8. The purine metabolism pathway. AMP is degraded into Hypoxanthine, and 
GMP into Xanthine. Hypoxanthine and Xanthine are oxidized by Xanthine Oxidase to 
produce Uric Acid. Adapted from George & Struthers, 2009.  
 
5.2 Association of Serum Uric Acid and Cardiovascular Disease 
 
The association between elevated SUA and CVD has been observed 
epidemiologically in many independent and archaic studies
112
. More recent evidence 
also suggests a potential causative role of elevated SUA in CVD, although there is no 
direct biological interaction defined for the association; and as of such SUA is not yet 
recognized as a true risk factor in CVD (World Heart Federation, 2014). Other 
previous studies have sought to define the relationship of SUA to CVD, via 
interactions of SUA to the many known risk factors associated with CVD. One such 
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interaction is the activation of the renin-angiotensin system, loss of the macula densa 
nitric oxidase system, and development of micro vascular disease through the 
production of reactive oxygen species facilitated by increased prooxidant activity of 
elevated SUA
113
. Another suggested interaction is the decrease in size of Low 
Density Lipoprotein (LDL) and High Density Lipoprotein (HDL). Abnormal lipid 
biology has long been recognized as a clear risk factor in Atherosclerosis, and 
evidence shows that elevated SUA promotes in vitro oxidation of LDL and HDL 
particles, attenuating their antioxidant properties and increases the likelihood of 
CVD
114
.An interesting observation in regards to current treatments of hyperuriceamia 
is the reduction in systolic blood pressure (SBP) and diastolic blood pressure (DBP) 
in chronic hyperuriceamia patients recently diagnosed with hypertension and who are 
treated with the XO inhibitor Allopurinol. Patients showed a decrease of 6.9 mm Hg 
in systolic BP, and a decrease of 5.1 mm Hg diastolic BP when treated with 
Allopurinol. In contrast, the placebo group showed a decrease of 2.0 mmHg systolic 
BP, and a decrease of 2.4 mm Hg diastolic BP
115
. In spite of this, no definitive 
biological mechanism has been reported, but activation of the renin-angiotensin 
system is a potential mechanism of action. Nonetheless, this interesting relationship 
requires further exploration to define Allopurinol as a therapeutic drug for 
hypertensive patients due to proposed adverse effects. 
 
5.2.1 Genetics of Serum Uric Acid levels 
 
Hyperuriceamia, and in general abnormal SUA levels, has been widely associated 
with variants in several genes through the implementation of Genome Wide 
Association Studies (GWAS). Abnormal SUA levels have an estimated heritability of 
40-70% 
116,117
. At present 46 loci have shown association with abnormal SUA levels, 
including the 18 most recent loci identified in a large meta-analysis on >140,000 
individual by Kottgen et al., 2013 (Table 8 and Figure 9). Of these 46, a Single 
Nucleotide Polymorphism (SNP) within the gene SLC2A9 has shown the most 
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independently replicated association in many studies
118,119,120
. SLC2A9 is a member 
of the SLC2A facilitative glucose transporter family, and has been described in its 
role as a urate transporter
121
. Another highly replicated association is within the 
ABCG2 gene, which encodes an ATP Binding Cassette protein, and has recently also 
been described as an urate transporter
122
. Defective urate transport and clearance is a 
clear mechanism in hyperuriceamia, and association with urate transport genes is not 
surprising. Nonetheless, whether variants in these genes are also associated with 
CVD remains to be elucidated. 
 
Loci Chromosome Sample Size Population Author 
PDZK1 1 Meta >140,000 European Kottgen A (2013) 
TRIM46 1 Meta >140,000 European Kottgen A (2013) 
GBAP1 1 Meta 71,149 Chinese Okada Y (2012) 
PPP1R12B 1 1,957 Korean Son C (2014) 
GCKR 2 Meta >140,000 European Kottgen A (2013) 
INHBB 2 Meta >140,000 European Kottgen A (2013) 
ORC4 2 Meta >140,000 European Kottgen A (2013) 
LRP2 2 ~14,700 Japanese Kamatani Y (2010) 
MUSTN1 3 Meta >140,000 European Kottgen A (2013) 
AC007953.1 3 1,017 African Americans Charles BA (2011) 
SLC2A9 4 Meta >140,000 European Kottgen A (2013) 
GLUT9 4 6,148 European Li S (2007) 
WDR1 4 1,017 African Americans Charles BA (2011) 
GLUT9 4 868 Old Amish McArdle PF (2008) 
ABCG2 4 Meta >140,000 European Kottgen A (2013) 
SEMA5A 5 1,300 European Karns R (2012) 
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TMEM171 5 Meta >140,000 European Kottgen A (2013) 
AL162718.1 6 1,017 African Americans Charles BA (2011) 
RREB1 6 Meta >140,000 European Kottgen A (2013) 
LRRC16A 6 Meta 28,141 European Kolz M (2009) 
SLC17A1 6 Meta 28,283 European Yang Q (2010) 
SLC17A3 6 7699 European Dehghan A (2008) 
VEGFA 6 Meta >140,000 European Kottgen A (2013) 
ARID1B 6 1,017 African Americans Charles BA (2011) 
MLXIPL 7 Meta >140,000 European Kottgen A (2013) 
PRKAG2 7 Meta >140,000 European Kottgen A (2013) 
STC1 8 Meta >140,000 European Kottgen A (2013) 
HNF4G 8 Meta >140,000 European Kottgen A (2013) 
RP11-523018.1 10 1,017 African Americans Charles BA (2011) 
ASAH2 10 Meta >140,000 European Kottgen A (2013) 
SLC16A9 10 Meta >140,000 European Kottgen A (2013) 
SLC22A11 11 Meta >140,000 European Kottgen A (2013) 
NRXN2 11 Meta >140,000 European Kottgen A (2013) 
MAP4K2 11 Meta 21,708 African Americans Tin A (2011) 
LTBP3 11 Meta >140,000 European Kottgen A (2013) 
INHBC 12 Meta >140,000 European Kottgen A (2013) 
PTPN11 12 Meta >140,000 European Kottgen A (2013) 
NRG4 15 Meta >140,000 European Kottgen A (2013) 
IGF1R 15 Meta >140,000 European Kottgen A (2013) 
NFAT5 16 Meta >140,000 European Kottgen A (2013) 
MAF 16 Meta >140,000 European Kottgen A (2013) 
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HLF 17 Meta >140,000 European Kottgen A (2013) 
C17orf82 17 Meta >140,000 European Kottgen A (2013) 
PRPSAP1 17 Meta >140,000 European Kottgen A (2013) 
MYO18B 22 1,017 African Americans Charles BA (2011) 
Table 8. Known Loci associated with Serum Uric Acid Levels, ordered by chromosome 
position. Sample size of discovery cohort, the population and author is provided. 
 
 
Figure 9. 28 genomic loci contain SNPs associated with SUA concentration. A manhattan 
plot showing –log10 P values of 10 previously known replicated loci, and 18 novel loci 
discovered in a large meta-analysis of >140,000 individuals. The gene located closest to 
the SNP with the lowest P value at each locus is listed. Loci in gray met one but not both 
replication criteria. Blue triangles represent loci containing SNPs with P values below 1 x 
10-25.Reproduced with permission from Köttgen et al., 2013. 
 
5.3 Potential usefulness of Mendelian Randomization  
 
To disentangle a potential causal relationship between SUA and CVD, we 
propose a Mendelian Randomization (MR) approach. MR was first proposed in 1986 
by Katanto evaluate whether low levels of LDL cholesterol increased cancer risk 
(Katan, 1986). Katan noted that observational studies had reported a higher risk of 
cancer in individuals with low levels of LDL, compared to subjects with normal or 
elevated LDL levels. However, a major limitation of observational studies that have 
identified an epidemiological association between an intermediate phenotype and an 
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outcome is whether these associations are causal or spurious due to problems of 
confounding and reverse causation. Reverse causality occurs when the outcome 
affects the levels of the intermediate phenotype, rather than the expected direction of 
effect. Confounding is when an unknown, or known, factor influences both the 
intermediate phenotype and the outcome of interest. 
MR implements the use of genetic variation, which are assigned randomly at 
conception, to infer causality of an intermediate phenotype to an outcome or 
disease
123
. Unlike a classical association study where only a single association is 
defined, a MR approach relies on the association between 3 distinct factors. First, the 
association of an instrumental variable (IV), a genetic variant, to the intermediate 
phenotype has to robust and well established in independently replicated studies. 
Second, the association of the IV and the outcome of interest, which can be 
determined by a qualitatively or quantitatively study design. And finally, estimates of 
these associations can hence, be used to infer causality of the intermediate phenotype 
to the outcome of interest (Figure 10)
124
. 
 
5.3.1 Limitations of Mendelian Randomization  
 
For a MR study to be successful, several limitations need to be addressed. Genotypic 
effects on phenotype are typically small so MR can require very large sample sizes. 
And hence, for MR to be an effective method there has to be a well-defined 
association of the IV to the intermediate phenotype, and in the context of a genetic 
analyses robust association of a SNP to the intermediate phenotype. Another core 
consideration of a MR analysis requires that no pleiotropy is present within the IV, 
and the interaction of the IV to the outcome is only mediated via the intermediate 
phenotype. Nonetheless, to completely evaluate the pleiotropic effects of an 
instrumental variable, both the function of the gene and its variants need to be known 
which is rarely the case and hence, a stringent selection criteria for these instrumental 
variables are required
125
. 
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MR studies are generally conducted with single IVs, but the use of independent 
multiple instrumental variables (mIV) to limit the effect of pleiotropy and increase 
statistical power has also been well implemented in some MR studies (Palmer et al., 
2012). However, mIV are more prone to other confounding such as population 
stratification and linkage disequilibrium LD) (Figure 10) Population stratification, a 
potential problem in all association studies, occurs when ancestral origins determine 
the prevalence of certain IV in the sample. Nonetheless, there is debate regarding the 
extent to which this can generate spurious associations, and several statistical 
techniques, such as Genomic Control, are commonly implemented in association 
studies to counter effect size inflation
126
. Confounding due to LD can occur when an 
IV, in high LD with another genetic variant, influences the outcome not through the 
intermediate phenotype, but through a different mechanism. However, selection of an 
IV that is shown to be in LD with a known genetic variant that is associated with the 
outcome but mediates its effect via the intermediate phenotype would increase the 
likelihood of inferring a true causal relationship. Furthermore, increasing statistical 
power by using independent mIV in different regions of the genome would 
significantly dampen confounding effects due to, either pleiotropy and/or LD, as 
genes in discrete genomic regions would unlikely have the same biological 
mechanisms
127
. Therefore, in repetition, a stringent IV selection criterion is essential 
to limit the possible biases imparted by the confounding factors. 
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Figure 10. Diagram showing the hypothesis underlying a classic Mendelian 
Randomization approach. Orange Arrows: Association 1, between the 
instrument variable (IV) and intermediate phenotype (IP), should be well 
established in literature. Association 2, between the IV and the outcome of 
interest (OI), should be mediated through the IP only. Association 3, 
between the intermediate phenotype and the OI, is the causal relationship 
inferred from the estimated values of association 1 and 2. Green Arrows: 
Possible limitations of a Mendelian Randomization study such as reverse 
causality and confounding via IV pleiotropy or LD. 
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5.4 Relationship between Serum Uric Acid and Cardiovascular Disease in 
Brisighella Heart Study: A Mendelian Randomization Analysis 
 
5.4.1 Hypothesis 
 
We hypothesized that increased SUA levels affect susceptibility to CVD and the 
genetic effects observed in cardiometabolic traits are mediated through their effect on 
SUA levels - investigating the evidence provided by the population based Brisighella 
Study. 
5.4.2  Aims 
 
The aim of this study was to implement a Mendelian Randomization approach to 
define a causal relationship between SUA and CVD. To this aim, we used genetic 
variants associated with SUA, by genotyping 1656 samples from the Brisighella 
Cohort using Fluidigm Integrated Fluidic Circuit (IFC) and TaqMan systems, as our 
instrumental variables. 
 
5.4.3 Research Plan 
 
Initially, we performed a comprehensive background literature search to identify 
SNPs associated with SUA levels allowed for efficient selection of variants to use in 
MR. Fluidigm IFC system required gDNA to be normalized and pre-amplified for the 
selected SNPs. Testing of two amplification methods determined the most 
appropriate. Genotypes from Fluidigm IFC and TaqMan systems were then quality 
controlled using the R statistical package. Association of the variants to the 
phenotype was tested using PLINK, and a Genetic Risk Score, using a simple allele 
counting method, determined causal relationship of the variants to CVD, and or, 
related traits. 
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5.4.4 Materials and Methods 
 
Detailed information of the Brisighella Heart Study has been published previously
128
. 
Briefly, it is a classic epidemiological study where 2939 randomly selected subjects 
(1491 men and 1448 women) from the northern Italian rural town of Brisighella were 
enrolled at baseline in year 1972. These subjects were aged 14-84 years, free of 
cardiovascular disease, and underwent follow-up examinations every 4 years. This 
included measurements of BMI, SBP, DBP, SUA, and Creatinine. Logistic traits such 
as Hypertensions (HTN), Hypercholesterolemia (HC) and whether they suffer from 
CHD was also recorded. Individual mortality and morbidity was also recorded (Table 
9) This study was conducted using gDNA extracted from blood by a standard 
extraction protocol from 1656individualsbetween 1973-2012 follow-up periods. 
 
SNP Selection 
 
A comprehensive list of SNPs associated with SUA discovered from a background 
literature search is provided . Several criteria had to be met for a SNP to be suitable 
for MR analysis. Firstly, the SNP had to be robustly and independently associated 
with SUA, which was determined using the published literature for the relevant SNP. 
Due to the recent publication of their meta-analysis by Kottgen et al., 2013, priority 
was given to their SNPs with the lowest p-values to ensure appropriate statistical 
association with SUA. Secondly, using the online resource dbSNP (build 37) and 
1000 genomes (CEU), all SNPs were checked for association with CVD and/or CVD 
risk factors and LD with other SNPs that may be associated with either; CVD 
directly, or CVD related traits such as HTN or obesity. This was to provide greater 
scope for a potential causal mechanism in SUA mediated CVD. Priority was given to 
SNPs that had direct association with CVD or CVD risk factors or were in LD (r
2
 ≥ 
0.2) with other SNPs associated with CVD or CVD risk factors. Only independent 
(approximately 250kb apart and no LD present r
2
< 0.2) SNPs were selected to ensure 
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efficient genome coverage. Lastly, non-synonymous SNPs were given priority over 
synonymous. The final 24 selected SNPs are listed in (Table 10) 
 
Total subjects (n) 1656 
Men 794 
Women 859 
  
Age (years)  
Mean (±) 53.20 (±18.06) 
Median 51 
  
Hyprecholestereamiaeamia (n)  
Yes (%) 596 
No (%) 886 
  
Diabetes (n)  
Yes (%) 70 
No (%) 1505 
  
Hypertension (n)  
Yes (%) 912 
No (%) 658 
  
Coronary Heart Disease (n)  
Yes (%) 38 
No (%) 1551 
  
BMI  (kg/m2)  
Mean (± SD) 26.46 (±4.54) 
Median 25.91 
  
Systolic Blood Pressure (mmol/Hq)  
Mean (± SD) 137.31 (±20.30) 
Median 135 
  
Diastolic Blood Pressure (mmol/Hg)  
Mean (± SD) 85.90 (±11.29) 
Median 86 
  
Fasting Uric Acid (mg/dL)  
Mean (± SD) 5.06 (±1.55) 
Median 4.9 
  
Creatinine (mg/dL)  
Mean (± SD) 0.93 (±0.18) 
Median 0.9 
Table 9. Subject Characteristics for Brisighella Heart Study Cohort 
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Table 10 . 24 selected SNPs to be used in MR analysis 
 
Genotyping 
 
All 24 TaqMan SNP genotyping assays were ordered from Life Technologies and 
were 40x concentrations apart from rs2231142, which was 20x. Once received all 
assays were stored at -20° C and covered in opaque tape to minimize photo bleaching 
rs ID 
C
h 
Position 
(b37) 
Locus 
Name 
Effe
ct 
(mg/
dL) 
P-Value SNP 
AAb 
Varia
tion 
Other 
Associatio
ns for 
SNP 
Other associations in the locus (approximate distance between the two SNPs-
SNP rsID(r2)) 
CEU 
MAFc 
(dbSN
P 
b126) 
Study 
First 
Authord 
and Date 
rs1471633 1 
145,723
,739 
PDZK1 
0.05
9 
1.2 × 
10–29 
C>A    0.45 
Kottgen 
A (2013) 
rs11264341 1 
155,151
,493 
TRIM4
6 
–
0.05
0 
6.2 × 
10–19 
C>T   Obesity(20kb)-rs11264330, Parkinsons(20kb)-rs12726330 0.44 
Kottgen 
A (2013) 
rs1260326 2 
27,730,
940 
GCKR 
0.07
4 
1.2 × 
10–44 
C>T 
Leu 
to Pro 
2hGlu,TG
, TC 
FI, FG, T2D, WC-TG, PL (10kb)-
rs780094(0.933)/rs780093(0.901)/rs1260333(0.676) 
0.42 
Kottgen 
A (2013) 
rs2307394 2 
148,716
,428 
ORC4 
–
0.02
9 
2.2 × 
10–8 
A>
G 
Asn 
to Ser 
 Response to statin therapy (220kb)-rs7584099(0.184) 0.38 
Kottgen 
A (2013) 
rs6770152 3 
53,100,
214 
MUST
N1 
–
0.04
4 
2.6 × 
10–16 
G>T   Height (20kb)-rs2336725(0.264), Ventricular contraction (200kb)-rs4687718 0.51 
Kottgen 
A (2013) 
rs12498742 4 
9,944,0
52 
SLC2A
9 
0.37
3 
0 
A>
G 
  CVD Risk factors -rs7671266(0.571)/rs4698036(0.525) 0.24 
Kottgen 
A (2013) 
rs2231142 4 
89,052,
323 
ABCG2 
0.21
7 
1.0 × 
10–134 
C>A 
Gln 
to 
Lys 
 
IBD (10kb)-rs4656958, Crohns (10kb+20kb)-rs2274910, Response to statin 
therapy (10kb)-rs1481012(0.92), Serum Metabolites (150kb)-rs1440581 
0.11 
Kottgen 
A (2013) 
rs675209 6 
7,102,0
84 
RREB1 
0.06
1 
1.3 × 
10–23 
C>T   
Adipose Tissue (10kb)-rs2842895, FG (100 kb)-rs2714337(0.283), Waist-
Hip ratio (100kb)-rs6931262 
0.71 
Kottgen 
A (2013) 
rs1165151 6 
25,821,
616 
SLC17
A1 
–
0.09
1 
7.0 × 
10–70 
A>C   
Fe(50kb+150kb)-rs932316/rs2274089/rs17270561/rs17342717, 
Platelet(50kb)-rs441460/rs12526480, Cimt(150kb)-rs4712972, 
CVD(150kb)- rs11754288(0.875),RBC Traits(200kb)-
rs17342717/rs1408272 
0.48 
Kottgen 
A (2013) 
rs729761 6 
43,804,
571 
VEGF
A 
–
0.04
7 
8.0 × 
10–16 
G>T   
Adiponectin(100kb)-rs998584, CHD+WHR (150 kb)-rs6905288, 
CKD(20kb)-rs881858(0.83), Thyroid Hormones(20kb+50kb)-
rs9472138/rs11755845, VEGF(50kb)-rs9472155/rs4513773 
0.75 
Kottgen 
A (2013) 
rs1178977 7 
72,857,
049 
MLXIP
L 
0.04
7 
1.2 × 
10–12 
A>
G 
  
TG, HDL (10kb-150kb)-
rs3812316(0.778)/rs2286276(0.666)/rs17145738(0.725)/rs714052(0.725)/rs1
178979(1.00)/rs2240466(0.725), Gamma GlutyTransferase(150kb)-
rs17145750(0.832)/rs12539316(0.697), Lipid Metabolism(150kb)-
rs13226650(0.945)/rs13247874(0.945), Obesity(125kb)-rs12666883 
0.18 
Kottgen 
A (2013) 
rs10480300 7 
151,406
,005 
PRKA
G2 
0.03
5 
4.1 × 
10–9 
C>T  
RBC 
Traits 
CKD(5kb)-rs7805747(1.00), Heamoglobin(10kb)-rs10224002(0.961) 0.25 
Kottgen 
A (2013) 
rs17786744 8 
23,777,
006 
STC1 
–
0.02
9 
1.4 × 
10–8 
A>
G 
Asn 
to Ser 
 
CKD(20kb)-rs10109414(0.935), Adipose(20kb)-rs7833268(0.125), Height 
(300kb)-rs1013209 
0.45 
Kottgen 
A (2013 
rs2941484 8 
76,478,
768 
HNF4
G 
0.04
4 
4.4 × 
10–17 
C>T   Obesity(130kb)-rs4735692, BMI(100kb)-rs2922763(0.201) 0.45 
Kottgen 
A (2013) 
rs10821905 
1
0 
52,646,
093 
ASAH2 
0.05
7 
7.4 × 
10–17 
A>
G 
   0.2 
Kottgen 
A (2013 
rs1171614 
1
0 
61,469,
538 
SLC16
A9 
–
0.07
9 
2.3 × 
10–28 
A>
G 
   0.8 
Kottgen 
A (2013) 
rs2078267 
1
1 
64,334,
114 
SLC22
A11 
–
0.07
3 
9.4 × 
10–38 
A>
G 
  
Obesity(20kb)-rs7124676(0.837), IBD(150kb)-rs559928, PBC(200kb)-
rs538147 
0.54 
Kottgen 
A (2013 
rs478607 
1
1 
64,478,
063 
NRXN2 
–
0.04
7 
4.4 × 
10–11 
A>
G 
  Obesity(100kb)-rs7124676, IBD(250kb)-rs559928, PBC(300kb)-rs538147 0.86 
Kottgen 
A (2013) 
rs3741414 
1
2 
57,844,
049 
INHBC 
–
0.07
2 
2.2 × 
10–25 
A>
G 
  TG+HDL(60KB)-rs11613352(0.959) 0.25 
Kottgen 
A (2013) 
rs653178 
1
2 
112,007
,756 
PTPN1
1 
–
0.03
5 
7.2 × 
10–12 
A>
G 
 
DBP, 
CKD, 
Celiac 
Disease 
CAD (130kb)-rs3184504(0.873), DBP/SBP (130kb)-rs3184504(0.873), LDL 
(70kb)-rs11065987(0.552), CHD(150kb)-rs11066015, Stroke(200kb)-
rs2238151(0.213), TG(200kb)-rs671 
0.56 
Kottgen 
A (2013) 
rs6598541 
1
6 
79,734,
987 
MAF 
–
0.03
2 
1.6 × 
10–9 
A>
G 
  
T2D(250kb)-rs17797882,Height(100kb)-rs7498403,Obesity(50kb)-
rs1424233,Thyroid(100kb)-
rs17767419(0.932)/rs3813579(0.333)/rs3813582(0.932) 
0.38 
Kottgen 
A (2013) 
rs7188445 
1
7 
59,465,
697 
C17orf
82 
0.04
3 
1.2 × 
10–8 
A>
G 
  
Creatinine(20kb)-rs8068318(0.437), Height (30kb)-rs2079795/rs757608, 
Obesity(150kb)-rs17513268 
0.17 
Kottgen 
A (2013) 
rs7224610 
1
5 
99,271,
135 
IGF1R 
0.04
3 
4.8 × 
10–15 
A>
G 
  Height (75kb)-rs2871865 0.7 
Kottgen 
A (2013 
rs2079742 
1
7 
53,364,
788 
HLF 
–
0.04
2 
5.4 × 
10–17 
A>C   Obesity(150kb)-rs11653011 0.58 
Kottgen 
A (2013 
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of the VIC and FAM fluorophores. Initially, all samples were to be genotyped using 
Fluidigm 192.24 Integrated Fluidic Circuits (IFC) system 
(http://www.fluidigm.com/chips-kits.html), which would have allowed for 
multiplexing of the 24 SNPs. However, after performing genotyping on the first 2 
IFCs, rs12498742 did not perform well, and provided spurious genotype calls and 
poor amplification when multiplexed, but worked as expected when tested as a 
singleplex on the TaqMan 7900ht system. Therefore, all SNPs were finally genotyped 
on 192.24 IFC with the exception of rs12498742that was genotyped using a 
singleplex TaqMan protocol. 
 
5.4.5 Results 
 
Single SNP association to Uric Acid and CVD related traits 
 
Association of genetic variants (n=24) to SUA showed, as expected, a positive effect 
of risk alleles in increasing levels of SUA (Table 11) We confirmed association for 
the most significantly associated, SNP rs12498742 (β = 0.41 per A allele; SE = 
0.052; p = 1.5 x 10
-15
) at locus SLC2A9, and report an effect size was in line with that 
stated in previous studies (Kamatani et al., 2010; Karns et al., 2012; Köttgen et al., 
2013; Tin et al., 2011; B. Yang et al., 2014). We also showed significant associations, 
before multiple testing correction, for 4 other SNPs; at locus ABCG2 for rs2231142 
(β = 0.23 per T allele; SE = 0.089; p = 0.0092), at locus VEGFA for rs729761 (β = 
0.12 per G allele; SE = 0.55; p = 0.0298), at locus PRKAG2 for rs10480300 (β = 0.10 
per T allele; SE = 0.051; p = 0.0483), and at locus SLC16A9 for rs1171614 (β = 0.19 
per C allele; SE = 0.054; p = 0.0005). After a Bonferroni Correction (p<0.002), only 
rs12498742 and rs1171614 survived (Table 11). 
Association of genetic variants to creatinine also showed several positive associations 
(p<0.05) before correction. The most significant association was observed at locus 
GCKR for rs1260326 (β = 0.019 per C allele; SE = 0.006; p = 0019), and also for 
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SNP variants; rs12498742 (β = 0.018 per A allele; SE = 0.007; p = 0.0072), 
rs1178977 (β = -0.017 per A allele; SE = 0.009; p = 0.0492), rs2078267 (β = 0.014 
per C allele; SE = 0.006; p = 0.0253), and rs7224610 (β = 0.012 per A allele; SE = 
0.006; p = 0.0482) at SLC2A9, MLXIPL, NRXN2, and IGF1R loci, respectively. After 
correcting for multiple testing only the association at rs1260326 survived (Table 
11Table 11). 
We detected only a single significant association, before correction, for BMI at locus 
SLC16A9for SNP rs10821905 (β = -0.11 per A allele; SE = 0.048; p = 0.0219), but 
after correction it is not significant. Similarly, we observed a single significant 
association for SBP at locus PRKAG2for SNP rs10480300 (β = 1.36 per T allele; SE 
= 0.65; p = 0.038), but did not survive Bonferroni correction. Interestingly, we 
observed several associations for DBP with the most significant being SNP 
rs2941484 (β = -0.86 per T allele; SE = 0.38; p = 0.0231) at locus HNF4Gand others 
for rs653178 (β = 0.82 per C allele; SE = 0.38; p = 0.0321) and rs2079742 (β = -1.13 
per C allele; SE = 0.501; p = 0.0246), MAF and HLF loci respectively. Unfortunately, 
after multiple testing correction none of the SNPs survived (Table 11) 
We identified 4 significant associations for CAD (Table 12), the most significant at 
locus RREB1for SNP rs675209(OR = 1.92 per T allele; 95% C.I = 1.16 -3.18p = 
0.0098), and also at loci MUSTN1, SLC17A1, and SLC16A9, respectively for SNPs; 
rs6770152 (OR = 0.54 per G allele; 95% C.I = 0.32 – 0.901; p = 0.0017), rs1165151 
(OR = 1.74 per G allele; 95% C.I = 1.09 – 2.80; p = 0.0198), and rs10821905 (OR = 
1.84 per A allele; 95% C.I = 1.092 – 3.101; p = 0.0202). None of the 24 genotyped 
variants showed association with HTN (Table 12). For HC, we showed 3 at least 
nominally significant associations for SNPs; rs12498742 (OR = 0.78 per A allele; 
95% C.I = 0.66 – 0.92; p = 0.003), rs17786744 (OR = 0.81per G allele; 95% C.I = 
0.70 – 0.95; p = 0.0084), and rs2079742 (OR = 0.79 per C allele; 95% C.I = 0.64 – 
0.96; p = 0.0192) at loci SLC2A9, STC1, and HLF, respectively. Finally, we also 
detected 3 significant associations for DB with the most significant being for SNP 
rs729761 (OR = 1.92 per G allele; 95% C.I = 1.19 – 3.11; p = 0.007) at locus 
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VEGFA. Others for SNPs; rs478607 (OR = 2.11 per A allele; 95% C.I = 1.10 – 4.06; 
p = 0.0218) and rs2307394 (OR = 0.66 per C allele; 95% C.I = 0.45 – 0.98; p = 
0.038) respectively at loci INHBC and ORC4. However, after Bonferroni correction 
none of the above associations remain significant (Table 12) 
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 URIC ACID 
CREA BMI SBP DBP 
CHR SNP BP 
Locus 
Name 
Alleles 
(effect/other) 
Sample Size Effect SE P Value Effect SE P Value Effect SE P Value Effect SE P Value Effect SE P Value 
1 rs1471633 145723739 PDZK1 A/C 1485 0.0552 0.0496 0.2659 0.0044 0.0063 0.4838 -0.0143 0.0376 0.7045 0.2747 0.6281 0.662 0.1393 0.3962 0.7252 
1 rs11264341 155151493 TRIM46 C/T 1544 0.0379 0.0494 0.4421 0.0035 0.0063 0.5854 -0.0155 0.0376 0.6807 -0.0263 0.625 0.9665 0.0079 0.3941 0.984 
2 rs1260326 27730940 GCKR C/T 1533 0.0164 0.0485 0.7354 0.0193 0.0062 0.0019 0.0156 0.0369 0.6727 0.0251 0.6134 0.9673 0.3023 0.3871 0.4348 
2 rs2307394 148716428 ORC4 C/T 1499 0.0107 0.0511 0.8344 -0.0009 0.0066 0.8933 -0.0029 0.039 0.9405 -0.9353 0.644 0.1466 -0.6862 0.4066 0.0917 
3 rs6770152 53100214 MUSTN1 G/T 1526 0.0483 0.0495 0.33 0.0015 0.0064 0.8091 -0.0442 0.0378 0.2421 0.0407 0.6294 0.9485 0.0831 0.3973 0.8343 
4 rs12498742 9944052 SLC2A9 A/G 1528 0.4143 0.0521 1.5 x 10
-15 
0.0183 0.0068 0.0072 -0.0247 0.0401 0.5377 -0.9804 0.6725 0.1451 0.2009 0.4233 0.6352 
4 rs2231142 89052323 ABCG2 T/G 1532 0.2307 0.0885 0.0092 0.0086 0.0114 0.4499 0.0056 0.0676 0.9341 0.7892 1.124 0.4829 0.046 0.7076 0.9482 
6 rs675209 7102084 RREB1 T/C 1528 0.0081 0.06 0.8922 0.0052 0.0077 0.497 -0.0496 0.0456 0.2775 -0.738 0.7585 0.3308 -0.1563 0.4784 0.7439 
6 rs1165151 25821616 SLC17A1 G/T 1532 0.0805 0.0484 0.0964 -0.0002 0.0062 0.971 0.0516 0.0368 0.1606 -0.5442 0.6122 0.3742 -0.3083 0.3861 0.4248 
6 rs729761 43804571 VEGFA G/T 1533 0.1193 0.0548 0.0296 0.013 0.0071 0.065 -0.0317 0.0418 0.4481 0.8882 0.6946 0.2012 0.8237 0.4376 0.06 
7 rs1178977 72857049 MLXIPL A/G 1522 0.0517 0.0671 0.4415 -0.017 0.0086 0.0492 0.0652 0.0507 0.1991 1.149 0.8455 0.1744 0.6654 0.5351 0.2139 
7 rs10480300 151406005 PRKAG2 T/C 1529 0.1013 0.0513 0.0483 0.0111 0.0066 0.0917 0.0019 0.0391 0.9612 1.362 0.6489 0.036 0.4837 0.4101 0.2384 
8 rs17786744 23777006 STC1 G/A 1531 0.0046 0.0498 0.9263 0.0027 0.0064 0.6668 -0.0022 0.0379 0.9534 -0.5857 0.6297 0.3524 -0.4674 0.397 0.2392 
8 rs2941484 76478768 HNF4G T/C 1532 0.0101 0.0475 0.8315 0.009 0.0061 0.1403 -0.0104 0.0362 0.7739 -1.102 0.6 0.0665 -0.8603 0.3783 0.0231 
10 rs10821905 52646093 ASAH2 A/G 1532 0.0628 0.0625 0.3154 0.0039 0.008 0.63 -0.1091 0.0475 0.0219 0.1774 0.7905 0.8224 0.5291 0.4999 0.29 
10 rs1171614 61469538 SLC16A9 C/T 1524 0.1896 0.0544 0.0005 0.0004 0.007 0.9569 0.0467 0.0415 0.2604 -1.191 0.6887 0.084 -0.2063 0.435 0.6354 
11 rs2078267 64334114 SLC22A11 C/T 1532 0.0567 0.048 0.2382 0.0138 0.0062 0.0253 0.0476 0.0365 0.1922 0.6785 0.6066 0.2636 0.1815 0.3829 0.6356 
11 rs478607 64478063 NRXN2 A/G 1533 0.0218 0.0691 0.7528 -0.0021 0.0089 0.8108 0.0697 0.0524 0.1834 0.7669 0.874 0.3804 -0.5264 0.5502 0.3389 
12 rs3741414 57844049 INHBC T/C 1531 0.0184 0.0672 0.7842 0.0143 0.0086 0.0964 0.0403 0.0512 0.4317 -0.5383 0.8496 0.5264 -0.1109 0.536 0.8362 
12 rs653178 112007756 PTPN11 C/T 1530 0.085 0.0478 0.0752 0.0037 0.0061 0.5493 -0.0342 0.0364 0.3481 0.8803 0.6053 0.146 0.8194 0.382 0.0321 
15 rs6598541 99271135 MAF A/G 1527 0.0887 0.0493 0.0719 -0.0086 0.0063 0.1726 0.0586 0.0375 0.1187 -0.1375 0.6241 0.8256 -0.1326 0.3937 0.7363 
16 rs7188445 79734987 C17orf82 G/A 1529 0.0047 0.05 0.9257 -0.0078 0.0064 0.2232 0.0126 0.038 0.7398 -0.2134 0.6328 0.736 -0.0256 0.399 0.9489 
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Table 11.Association of 24 Uric Acid associated SNPs to Uric Acid and CVD related quantitative traits. Abbreviations: CREA 
– Creatinine, BMI – Body Mass Index, SBP – Systolic Blood Pressure, DBP – Diastolic Blood Pressure. P values in black bold 
show significantly associated SNPs before Bonferroni Correction, P values in red bold show SNPs that survive after multiple 
testing corrections. 
 
 
 
 
 
 
 
 
 
 
 
 
 
17 rs7224610 53364788 IGF1R A/C 1531 0.028 0.0472 0.553 0.0121 0.0061 0.0462 -0.0058 0.0359 0.8722 0.5462 0.5977 0.3609 0.3186 0.3769 0.3981 
17 rs2079742 59465697 HLF C/T 1527 0.0639 
0.063 0.3101 0.0149 0.0081 0.0657 0.0159 0.048 0.7398 0.6895 0.7967 0.3869 -1.129 0.5016 0.0245 
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     CAD HTN HC DB 
CHR SNP BP 
Locus 
Name 
Alleles (effect/other) OR (95% Confidence Intervals) P Value OR (95% Confidence Intervals) P Value OR (95% Confidence Intervals) P Value OR (95% Confidence Intervals) P Value 
1 rs1471633 145723739 PDZK1 A/C 1.3729 (0.8467 - 2.2272) 0.1973 0.9852 (0.8496 - 1.1413) 0.8395 1.15 (0.9862 - 1.3414) 0.0753 1.1261 (0.7924 - 1.6) 0.5072 
1 rs11264341 155151493 TRIM46 C/T 0.7645 (0.4808 - 1.2164) 0.256 1.0397 (0.8961 - 1.2058) 0.607 0.9346 (0.8006 - 1.0912) 0.3931 0.9276 (0.654 - 1.3149) 0.6725 
2 rs1260326 27730940 GCKR C/T 0.9932 (0.6252 - 1.578) 0.977 0.9656 (0.835 - 1.116) 0.6361 0.9195 (0.7904 - 1.07) 0.2768 1.099 (0.7809 - 1.547) 0.5875 
2 rs2307394 148716428 ORC4 C/T 0.9785 (0.5988 - 1.599) 0.931 0.88 (0.7554 - 1.025) 0.1009 0.9385 (0.7997 - 1.101) 0.4369 0.6606 (0.4473 - 0.9756) 0.036 
3 rs6770152 53100214 MUSTN1 G/T 0.5371 (0.3199 - 0.9018) 0.017 0.9998 (0.8624 - 1.159) 0.9984 1.124 (0.9639 - 1.311) 0.1357 1.21 (0.8579 - 1.706) 0.2767 
4 rs12498742 9944052 SLC2A9 A/G 0.7446 (0.4572 - 1.212) 0.2337 0.9699 (0.8278 - 1.1366) 0.7069 0.78 (0.6618 - 0.9191) 0.003 1.0898 (0.7457 - 1.5924) 0.6568 
4 rs2231142 89052323 ABCG2 T/G 1.445 (0.6852 - 3.046) 0.3312 0.9579 (0.7323 - 1.253) 0.7537 1.022 (0.7688 - 1.357) 0.8834 0.919 (0.4759 - 1.775) 0.8014 
6 rs675209 7102084 RREB1 T/C 1.92 (1.16 - 3.177) 0.0098 0.9657 (0.806 - 1.157) 0.7051 1.017 (0.8419 - 1.229) 0.8595 0.8402 (0.5359 - 1.317) 0.4476 
6 rs1165151 25821616 SLC17A1 G/T 1.742 (1.086 - 2.793) 0.0198 0.9671 (0.8365 - 1.118) 0.6511 1.098 (0.9443 - 1.278) 0.2238 0.9321 (0.6615 - 1.314) 0.688 
6 rs729761 43804571 VEGFA G/T 0.7722 (0.4615 - 1.2928) 0.3244 1.0371 (0.8764 - 1.2277) 0.6723 1.1689 (0.9785 - 1.3961) 0.0848 1.9201 (1.1862 - 3.1085) 0.007 
7 rs1178977 72857049 MLXIPL A/G 0.9542 (0.5102 - 1.7841) 0.8829 1.1534 (0.9452 - 1.4073) 0.1596 0.993 (0.8058 - 1.2244) 0.9488 0.9407 (0.5893 - 1.502) 0.798 
7 rs10480300 151406005 PRKAG2 T/C 1.025 (0.6226 - 1.687) 0.9231 1.087 (0.9284 - 1.273) 0.3 1.041 (0.8842 - 1.225) 0.6304 1.104 (0.7663 - 1.59) 0.5959 
8 rs17786744 23777006 STC1 G/A 1.067 (0.6701 - 1.7) 0.7836 0.9612 (0.8298 - 1.113) 0.5974 0.8133 (0.6974 - 0.9484) 0.0084 0.9239 (0.6517 - 1.31) 0.6564 
8 rs2941484 76478768 HNF4G T/C 1.01 (0.6341 - 1.609) 0.9661 0.9705 (0.8385 - 1.123) 0.6877 0.9253 (0.7944 - 1.078) 0.3178 1.375 (0.977 - 1.936) 0.0667 
10 rs10821905 52646093 ASAH2 A/G 1.84 (1.092 - 3.101) 0.0202 1.034 (0.8522 - 1.253) 0.7376 1.068 (0.8739 - 1.305) 0.5211 0.9175 (0.5756 - 1.462) 0.7174 
10 rs1171614 61469538 SLC16A9 C/T 0.8937 (0.5313 - 1.5026) 0.6711 1.0004 (0.846 - 1.1829) 0.996 1.1352 (0.9533 - 1.3521) 0.1552 0.8368 (0.5718 - 1.2237) 0.357 
11 rs2078267 64334114 SLC22A11 C/T 1.3609 (0.8453 - 2.1915) 0.2033 1.1067 (0.9569 - 1.2794) 0.1708 0.9551 (0.821 - 1.1104) 0.5473 1.0867 (0.771 - 1.5314) 0.6348 
11 rs478607 64478063 NRXN2 A/G 0.7593 (0.4137 - 1.3945) 0.3735 1.0065 (0.817 - 1.2399) 0.9511 0.9756 (0.7843 - 1.2133) 0.8233 2.1119 (1.1001 - 4.0552) 0.0216 
12 rs3741414 57844049 INHBC T/C 1.202 (0.6552 - 2.206) 0.5515 0.9351 (0.7641 - 1.144) 0.5152 0.8857 (0.7152 - 1.097) 0.2658 0.7937 (0.4728 - 1.332) 0.3811 
12 rs653178 112007756 PTPN11 C/T 1.002 (0.6318 - 1.59) 0.9921 1.108 (0.9583 - 1.281) 0.166 1.019 (0.876 - 1.185) 0.8087 0.9733 (0.6913 - 1.37) 0.8767 
15 rs6598541 99271135 MAF A/G 0.6315 (0.3839 - 1.039) 0.068 0.9352 (0.8071 - 1.084) 0.3723 0.9181 (0.7871 - 1.071) 0.2762 1.105 (0.7829 - 1.561) 0.5692 
16 rs7188445 79734987 C17orf82 G/A 1.2478 (0.7348 - 2.1195) 0.412 0.956 (0.817 - 1.1187) 0.5748 0.9785 (0.8306 - 1.153) 0.7967 0.9461 (0.6553 - 1.3654) 0.7671 
17 rs7224610 53364788 IGF1R A/C 0.9346 (0.5851 - 1.4914) 0.7759 1.047 (0.9058 - 1.2105) 0.5353 0.9728 (0.8361 - 1.1315) 0.7189 1.0858 (0.7698 - 1.5307) 0.6387 
17 rs2079742 59465697 HLF C/T 1.099 (0.6094 - 1.981) 0.7544 0.9878 (0.8164 - 1.195) 0.8992 0.7859 (0.6422 - 0.9618) 0.0192 1.165 (0.7564 - 1.794) 0.4879 
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Table 12. Association of 24 Uric Acid associated SNPs to CVD related binary traits.Abbreviations: CAD – Coronary Artery 
Disease, HTN – Hypertension, HC – Hyprecholestereamia, DB - Diabetes. P values in black bold show significantly 
associated SNPs before Bonferroni Correction, P values in red bold show SNPs that survive after multiple testing corrections 
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5.4.6-Genetic Risk Score association to Uric Acid and CVD related traits –  
Mendelian Randomization 
 
We identified at least nominally significant causal estimates for the effect of uric acid 
on creatinine (p = 0.0017) (Table 13) For other quantitative and binary traits we 
haven’t observed any significant causal relationship (Table 13) 
The IV estimators for creatinine show a causal effect of higher uric acid levels on the 
levels of creatinine (β = 0.072 (0.034 – 0.11); SE = 0.023).  
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Table 13.Mendelian Randomization results on effect of Serum Uric Acid on CVD 
related 
 
 
 
 
 
    IV Estimator 
GRS Traits â (95% C.I) SE P-Value â (95% C.I) SE P-Value 
CREA 0.0046 (0.0022-0.0071) 0.0012 0.0002 0.0727 (0.0341-0.1112) 0.0232 0.0017 
BMI 0.0183 (-0.0453-0.0819) 0.0324 0.572 0.2844 (-0.7038-1.2727) 0.5061 0.574 
DBP 0.1114 (-0.0476-0.2705) 0.0811 0.17 1.7309 (-0.7408-4.2028) 1.294 0.181 
SBP 0.1424 (-0.1443-0.4292) 0.1462 0.33 2.2122 (-2.243-6.6682) 2.302 0.3365 
       
    IV Estimator 
GRS Phenotypes OR (95% C.I) SE P-Value OR (95% C.I) SE P-Value 
CAD 1.0249 (0.9378-1.131) 0.0483 0.6101 0.961 (0.8794-1.0605) 0.0463 0.6114 
DB 1.05336 (0.9823-1.1344) 0.0369 0.159 0.9876 (0.921-1.0637) 0.036 0.1706 
HC 0.9958 (0.9667-1.0258) 0.0151 0.781 0.9337 (0.9064-0.9619) 0.0171 0.7812 
HTN 1.0284 (0.9997-1.0581) 0.0144 0.0524 0.9643 (0.9374-0.9922) 0.0167 0.0654
a 
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5.4.7 – Discussion 
 
We attempted to find a causal relationship between SUA and CVD/CVD related 
traits, a relationship that has been previously postulated in many observational 
studies, by implementing a Mendelian randomization approach and using genetic 
variants associated with SUA levels as our instrumental variable. Initially, through an 
extensive literature search, we identified known genetic variants associated with SUA 
levels. We devised a set of criteria to select 24 genetic variants, from the complete list 
of researched variants, to efficiently and effectively allow greater power to detect any 
causal relationship between SUA and CVD. In the past the use of a single 
instrumental variable in MR analysis was considered appropriate however, due to the 
fact that the use of genetic variants, which impart very small overall risk, requires 
multiple instrumental variables to be used to increase statistical association to the 
intermediate phenotype. This increases the likelihood of finding a true causal 
association to the outcome of interest, and reduces some of the limitations that 
inherently companion a MR analysis such as LD. Hence, careful selection of 
independent SNPs overcomes any unfavorable LD between IVs and also allows 
inclusion of genetic variants that might be in close vicinity, or within a locus that is 
already associated with CVD or a CVD related trait. 
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6.  A view towards the future, beginning from the past 
 
6.1 Genomic correlates of atherosclerosis in Ancient Humans 
 
Twenty-first century humans often think that much of the heart disease we suffer is 
the consequence of our modern lifestyle. We live sedentary, mentally stressful lives, 
consume large amounts of calories from ill chosen foods, indulge sugar and salt in 
high quantities, and are exposed to high levels of environmental toxins, including 
tobacco smoke. To avoid dying of a heart attack, we are urged to engage in regular 
exercise; maintain an ideal body weight; avoid unsaturated fat, salt, and sugar; avoid 
smoke; and take medicine to keep our blood pressure, lipid levels, and blood sugar in 
an ideal range. Perhaps we think nostalgically of our ancestors who lived a purer life 
and did not have to engage in corrective actions to prevent heart disease. 
Our ancestors going back thousands of years show signs of atherosclerosis, as 
suggested by modern research using CT to detect evidence of calcium deposits 
associated with atherosclerotic plaques in the arteries of mummies as old as 5,000 
years. Even though our human ancestors lived far different lives than we do, their 
environments and lifestyles were not protecting them against the development of 
atherosclerosis. 
What is similar between now and then is the human genetic material, our genome, 
including ancient polymorphisms that were uncovered to predispose the carrier to the 
development of atherosclerotic cardiovascular disease. Seminal studies of genetic 
material obtained from 5,300-year-old Ötzi showed mutations in the 9p21 
chromosomal region identical to SNP identified in contemporary humans that are 
strong predictors for the development of CAD. Our ancient ancestors were certainly 
susceptible to many other conditions, such as infectious diseases, nutritional 
deprivation, and trauma, which often resulted in an early age death, before athero- 
sclerotic heart disease became clinically manifest. 
Nevertheless, the study of ancient humans and the investigation of the interaction 
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between environmental and genetic influences on the development of heart disease 
may provide unique pathophysiologic insights and lead to more effective prevention 
and treatment of the most common cause of death in the modern world. 
Paleogenetics offers a unique opportunity to study human evolution, population 
dynamics, and disease evolution in situ. Although histologic and computed x-ray 
tomographic investigations of ancient mummies have clearly shown that 
atherosclerosis has been present in humans for more than 5,000 years, limited data 
are available on the presence of genetic predisposition for cardiovascular disease in 
ancient human populations. In a previous whole-genome study of the Tyrolean 
Iceman, a 5,300 year old glacier mummy from the Alps, an increased risk for 
coronary heart disease was detected. The Iceman’s genome revealed several single 
nucleotide polymorphisms that are linked with cardiovascular disease in genome-
wide association studies. Future genetic studies of ancient humans from various 
geographic origins and time periods have the potential to provide more insights into 
the presence and possible changes of genetic risk factors in our ancestors.  
6.2 1000 years of genetic variability in Brisighella’s population: survey on the 
predisposition to cardiovascular diseases from the XIst century today 
 
Genetic analysis of biological samples of the past allows to explore fascinating new 
Research horizons through the ability to analyze the genomes of individuals who 
lived in distant times. This area of research has many possible applications, which are 
based on the analysis of ancient DNA: evolutionary studies, identification of 
infectious or genetic diseases, staff identification, definition of family relationships 
between individuals and determination of characteristics or phenotypic markers 
related to specific diseases, as well as a reconstruction of the diet and genetic 
characterization of human groups in the past. 
The success of these studies suggests that the application of the latest technologies in 
the field of paleogenetics can bring significant contributions in the study of 
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preparation/genetic resistance to diseases with high incidence in the present 
population, among which cardiovascular ones surely play an important role. In 
particular, the knowledge of any changes, during time, of the frequencies of the 
markers correlated with the above pathologies and possible diachronic changes in 
DNA induced by epigenetic phenomena, could serve as an appropriate understanding 
of the pathogenesis of these diseases and their prevention. 
However, despite some studies based on histological and computed tomographic 
analysis have shown the presence of atherosclerosis in populations dating back 
over 5000 year 
129,130there are few data regarding the preparation to cardiovascular 
diseases in ancient human populations. 
Currently, in one individual of the past, the man of Similaun, dating back to about 
5300 years, the presence of polymorphisms (ie single nucleotide genetic 
modifications) related to the risk of coronary diseases
131,132
has been investigated. 
Among the polymorphisms related to the risk of cardiovascular diseases, the 
chromosomal region 9p21, already implicated in the pathogenesis of cancer
133
, was 
the subject of several studies in 2007,independent on the human genome that have 
reported the association of the same locus on chromosome 9p21 with coronary artery 
disease and myocardial infarction
134,135
. 
This discovery has led to a considerable increase of further investigations that have 
largely confirmed the preliminary data and the identification of other genetic 
variations closely associated with cardiovascular events 
136
.Alongside these studies, 
recent research gives a glimpse of the role that epigenetic DNA modifications can 
have in transforming environmental stimuli inheritable genetic expressions can 
influence significantly, even in later generations, the susceptibility to diseases. In 
particular, as well as in malignancies
137
, neurodegenerative
138
 and metabolic 
diseases
139
, epimutations of DNA (for example of hyper- or hypomethylation 
processes) appear to have a0 significant role in the pathogenesis of atherosclerosis 
and cardiovascular related disease
140
. 
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As for individuals of the past , the human genome of the Iceman has been entirely 
sequenced in 2012 and the analysis of the data obtained showed that this individual 
had a high genetic predisposition to cardiovascular inauspicious events, such as 
highlighted by a study of some genetic polymorphisms associated with 
cardiovascular risk previously identified in genome-wide association studies ().  
 
Table 14. SNP related to cardiovascular disease identified in the Iceman genome 
 
However, as far as we know, there are no systematic studies, at level of ancient 
people, in particular the second at diachronic perspective, both as regards genetic 
variants, and associated with epimutations in cardiovascular lesions. 
With a view to laying the foundations for an integrated project of biology, genetics 
and medicine inhuman field , the following project has as main objective the analysis 
of the preparation of genetic cardiovascular diseases in the population of Brisighella ( 
RA ) during a span of about 1000 years. 
The peculiarity of this research project lies in the ability to conduct a study on genetic 
markers related to cardiovascular diseases on the territory of Brisighella, with the 
extraordinary opportunity to expand the chronological horizon of the already 
established DNA biobank. 
In order to study the distribution of polymorphisms related to cardiovascular disease 
in the people of Brisighella from the ninth century to the present and correlate them 
with lifestyle and diet, it aims to address the following analysis : 
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1 ) verifying genetic continuity between the finding buried in the castle and the 
current Rontana people of Brisighella , previously sampled and which constitute the 
current DNA biobank ( Brisighella Heart Study Biobank ) . The analysis will be 
carried out through the study of markers uniparental ( hypervariable region 1 - HVR1 
of mitochondrial DNA polymorphisms Y chromosome ) that allow to identify and 
follow the female parental lines and men's long subsequent generations; 
2 ) analysing the presence of genetic variants related to cardiovascular disease 
identified in the association studies published in the literature in the ancient and 
modern population of Brisighella ; 
3 ) reconstruction of the style of life and state of health of ancient populations 
through anthropological and paleopathological study; 
4 ) reconstruction of the ancient population diet through stable carbon and nitrogen 
isotope analysis; 
5 ) extrapolation of data on lifestyle and diet for selected modern standards in the 
biobank ;  
The study of ancient humans and a better understanding of the interaction between 
environmental and genetic influences on the development of heart diseases may lead 
to a more effective prevention and treatment of the most common cause of death in 
the modern world. 
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